
==== Front
Calcif Tissue Int
Calcif Tissue Int
Calcified Tissue International
0171-967X
1432-0827
Springer US New York

39078512
1261
10.1007/s00223-024-01261-w
Review
The Relationship between Sclerostin and Kidney Transplantation Mineral Bone Disorders: A Molecule of Controversies
http://orcid.org/0000-0002-1369-3657
Afsar Baris afsarbrs@yahoo.com

12
Afsar Rengin Elsurer 12
Caliskan Yasar 2
Lentine Krista L. 2
1 https://ror.org/04fjtte88 grid.45978.37 0000 0001 2155 8589 Department of Nephrology, School of Medicine, Suleyman Demirel University, Isparta, Turkey
2 grid.412359.8 0000 0004 0457 3148 Department of Nephrology, Saint Loui University, Saint Louis University Hospital, Saint Louis, MO USA
30 7 2024
30 7 2024
2024
115 4 339361
5 5 2024
6 7 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Kidney transplantation is the most effective treatment option for most patients with end-stage kidney disease due to reduced mortality, decreased cardiovascular events and increased quality of life compared to patients treated with dialysis. However, kidney transplantation is not devoid of both acute and chronic complications including mineral bone disorders (MBD) which are already present in patients with chronic kidney disease (CKD) before kidney transplantation. The natural history of MBD after kidney transplantation is variable and new markers are needed to define MBD after kidney transplantation. One of these promising molecules is sclerostin. The main action of sclerostin is to inhibit bone formation and mineralization by blocking osteoblast differentiation and function. In kidney transplant recipients (KTRs), various studies have shown that sclerostin is associated with graft function, bone parameters, vascular calcification, and arterial stiffness although non-uniformly. Furthermore, data for inhibition of sclerostin with monoclonal antibody romosozumab for treatment of osteoporosis is available for general population but not in KTRs which osteoporosis is highly prevalent. In this narrative review, we have summarized the studies investigating the change of sclerostin before and after kidney transplantation, the relationship between sclerostin and laboratory parameters, bone metabolism and vascular calcification in the context of kidney transplantation. We also pointed out the uncertainties, explained the causes of divergent findings and suggest further potential study topics regarding sclerostin in kidney transplantation.

Keywords

Bone
Chronic kidney disease
Kidney transplantation
Sclerostin
Vascular calcification
Suleyman Demirel UniversityOpen access funding provided by the Scientific and Technological Research Council of Türkiye (TÜBİTAK).

issue-copyright-statement© Springer Science+Business Media, LLC, part of Springer Nature 2024
==== Body
pmcIntroduction

Kidney transplantation is the treatment of choice for most patients with end-stage kidney disease due to reduced mortality, decreased cardiovascular events, and increased quality of life compared to patients treated with dialysis [1]. However, kidney transplantation is not devoid of both acute and chronic complications including acute rejection, infections, cardiovascular events, and chronic allograft failure. With the development of new immunosuppressive regimens and improved biomarkers for rejection and graft injury surveillance, acute rejection episodes decreased but long-term kidney allograft survival has not improved in parallel and patient mortality exceeds that of the general population [2]. Non-immune complications of kidney transplantation include infections, malignancy, cardiovascular disease, and mineral bone disorders (MBD). To improve long-term patient survival, new management strategies are needed. One of these strategies is to find new biomarkers to facilitate early diagnosis and management of long-term, non-immune complications.

Mineral and bone disorders which are already present in both dialysis dependent and independent chronic kidney disease (CKD) patients may persist after kidney transplantation [3]. Although the name CKD–MBD suggest the problem is on bone metabolism, CKD–MBD is a systemic disorder including: (i) abnormalities of calcium, phosphorus, parathyroid hormone (PTH), or vitamin D metabolism; (ii) abnormalities in bone turnover, mineralization (e.g., osteoporosis), bone volume and (iii) vascular or other soft tissue calcification [4] or variable combinations of these. Indeed, in KTRs, crosstalk between kidney, arteries and bone via molecules and signaling pathways play a role in the development of CKD–MBD [5, 6] and sclerostin is one of these of molecules. After kidney transplantation, various pathologies such as hypercalcemia, hypophosphatemia, persistent hyperparathyroidism, de novo hyperparathyroidism, osteomalacia, osteopenia, osteoporosis, and vascular calcification may still be observed [6, 7]. Indeed, sclerostin has been considered as a new biomarker in CKD–MBD [8] which has been associated with various clinical, laboratory, and bone parameters, but with conflicting results. There are also various studies investigating the role of sclerostin in various aspects (parameters of bone metabolism, bone volume, bone remodeling, vascular calcification etc.) in kidney transplant recipients (KTRs) with divergent results. To advance understanding of the role of sclerostin in MBD physiology in the context of kidney transplantation, we conducted a review of studies investigating the changes in sclerostin before and after kidney transplantation, the relationship between sclerostin and laboratory parameters, as well as bone metabolism and vascular calcification in the context of kidney transplantation.

Methods

We performed (BA and REA) review of the literature in English language until March 2024 using major online databases (PubMed, Scopus, Web of Science, Cochrane Library and Google Scholar) using the key words “sclerostin renal transplantation,” “sclerostin and kidney transplantation,” “sclerostin and kidney graft failure,” “sclerostin cardiovascular disorders and renal transplantation,” “sclerostin cardiovascular disorders and kidney transplantation,” “sclerostin bone mineral disorders and kidney transplantation,” “sclerostin bone mineral disorders and renal transplantation.” After screening of the studies, only studies in the context of kidney transplantation were included. We included both cross-sectional, longitudinal, and interventional studies. The flow chart of included studies are shown in Fig. 1.Fig. 1 Flow chart of included studies

Results

The studies regarding sclerostin measurements, correlates of clinical, biochemical, bone parameters, and vascular calcifications with sclerostin in the context of kidney transplantation are summarized in Table 1. The studies are heterogeneous with respect to design, patient’s characteristics, follow-up period, and outcome measures. Some studies are cross-sectional [9–11] and some studies are longitudinal [12–16]. Furthermore, sclerostin measurements were measured before in kidney transplant in some studies (baseline sclerostin measurements) [17, 18] others measured sclerostin levels at post-kidney transplantation [19–21] and others measured sclerostin levels both baseline (before kidney transplantation) and after kidney transplantation [22, 23]. Table 1 Studies summarizing sclerostin assessment in the context of kidney transplantation

References	Methods	Specific results for sclerostin levels and bone parameters	Graft function	Sclerostin hemodynamic alterations MACE, mortality	
Bonani et al. [23]	– Serum sclerostin measured before and during the first year of kidney transplantation in 42 KTRs and its association with parameters of bone mineral metabolism and with bone mineral density

– Participants receive vitamin D (800 IU/day) and half of the patients were treated with denosumab (60 mg subcutaneous every 6 months) as part of the study protocol

– Sclerostin was measured by ELISA (TecoMedical)

	– Pre-transplant serum sclerostin elevated in all patients (61.8 ± 32.3 pmol/l) but within 15 days after kidney transplantation, sclerostin levels dropped to 21.0 ± 14.7 pmol/l and subsequently increased to 23.8 ± 14.9 and 28.0 ± 16.8 pmol/l after 6 and 12 months, respectively (P < 0.001)

– No correlation was found between post-transplant sclerostin and bone mineral density

– Tacrolimus, cyclosporine, calcium, bisphosphonates, cinacalcet, denosumab did not significantly associate with the post-transplant sclerostin

	No association between GFR and sclerostin trajectory	NDA	
Tomei et al. [112]	– In 19 post-menopausal KTRs and in 12 age matched post-menopausal CKD patients serum levels of sclerostin, DKK1, N-terminal procollagen type 1, bone-specific alkaline phosphatase, and serum C-terminal telopeptides of type I collagen measured

– Sclerostin levels were measured with an enzyme immunoassay (Biomedica)

	– Sclerostin similar among KTRs and CKD (absolute values are not given)

– Sclerostin positively correlated with serum phosphorus in multivariate analysis

	– Sclerostin negatively correlated with estimated GFR in multivariate analysis	NDA	
Evenepoel et al. [16]	– Coronary artery calcification (CAC) and aortic calcifications measured by CT in 268 prevalent KTRs at baseline and re-measured in 189 patients after a median follow-up of 4.4 years

– Baseline serum sclerostin levels were assessed on stored blood samples

– Serum sclerostin was determined with an ELISA (TecoMedical)

	– The median sclerostin level was 0.84 (0.62–1.10) ng/ml	– GFR tended to be lower in KTRs with sclerostin above median vs. below median (48.7 vs. 54.2 ml/min/1.72 m2, respectively, P 0.06)	– There is positive correlation between CAC, CAC progression (occurred in 47.1% KTRs), and baseline sclerostin in univariate analysis which was lost in multivariate analysis

– Baseline aortic calcification was positively correlated with sclerostin in univariate analysis which was reversed in multivariate analysis (lower sclerostin higher aortic calcification)

– Progression of aortic calcification (occurred in 45.5% KTRs) was not associated with baseline serum sclerostin in univariate and multivariate analysis

	
Venner et al. [21]	– Microarray analysis of kidney transplant biopsies performed to identify the changes in pure antibody-mediated rejection	– In 703 biopsies, 2603 transcripts were significantly changed in antibody-mediated rejection vs. all other biopsies

– Sclerostin transcript decreased in biopsies of antibody-mediated rejection which reflect expression in the normal renal microcirculation and loss with endothelial dedifferentiation

	NDA	NDA	
Evenepoel et al. [12]	– 50 De novo KTRs, 23 KTRs undergoing parathyroidectomy and in 50 CKD patients are observed in a longitudinal cohort study for 1 year

– Serum sclerostin was determined with an ELISA (TecoMedical)

	– Median serum sclerostin levels decreased by 61.2% during the first 3 months after kidney transplantation (1.24 vs. 0.44 ng/mL, P < 0.0001) but increased between 3 and 12 months toward levels observed in CKD counterparts (0.63 ng/ml)

– Increase of sclerostin between 3 and 12 months significantly correlated with the decrease of PTH in the same period

– PTH independently associated with lower sclerostin both at time of kidney transplantation and at 1 year

– Sclerostin significantly increased after parathyroidectomy (0.49 vs. 0.32 ng/ml)

– Male sex, lower eGFR, and lower PTH were significantly associated with higher sclerostin which explain 38% of the variation of circulating sclerostin

	– Lower eGFR was associated with higher sclerostin	NDA	
Hsu et al. [11]	– In 68 KTRs, brachial-ankle PWV measured which greater than 14.0 m/s was determined as high arterial stiffness

– Sclerostin levels were measured with an enzyme immunoassay (Biomedica)

	– Mean sclerostin levels were 69.61 ± 26.04 pmol/l

– Age, phosphorus, and log osteoprotegerin were positively associated with sclerostin

– No significant correlation observed between sclerostin and Intact PTH

	– eGFR was negatively correlated with sclerostin levels	30 KTRs (44.1%) with high arterial stiffness had higher sclerostin compared to KTRs with low arterial stiffness: 71.06 ± 23.52 vs. 50.57 ± 24.57 pmol/l

– In multivariate analysis, sclerostin (OR:1.052, 95% CI 1.007–1.099) was independent predictor of arterial stiffness

	
Makówka et al. [36]	– In 35 KTRs, changes of mineral and bone biomarkers including sclerostin were measured in 9-month period

– Urine sclerostin/creatinine ratio was assessed in parallel from month 1 after kidney transplantation

– Serum sclerostin was determined with an ELISA (TecoMedical)

	– Sclerostin levels were 1.95 ± 1.13, 1.51 ± 1.15, 1.2 ± 1.07, 0.84 ± 0.7, 0.99 ± 0.79, 1.05 ± 0.87, 1.24 ± 0.89, 0.85 ± 0.51, 0.92 ± 0.74, 1.35 ± 1.11 ng/ml, at Day 0, Week 1, Week 2, Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 9, respectively, showing 31% decrease from Days 0 at Month 9	– There was a significant increase in urinary elimination of sclerostin starting from the second month after transplantation	NDA	
Tartaglione et al. [9]	– In 80 KTRs the relationship between serum sclerostin eGFR, calcium, phosphate, AP, iPTH, klotho, intact FGF-23, 25D and 1, 25D. 30 Healthy subjects served as control

– Sclerostin levels were measured with sandwich ELISA kit (Biomedica)

	– Sclerostin not different in KTRs and controls (23.7 pmol/l vs. 26.6 pmol/l, respectively)

– Sclerostin correlated negatively with AP and positively with FGF-23 and 25D suggesting anti-anabolic role and inhibitory action on vitamin D of sclerostin action

– AP and 1, 25D were negative and 25D and Klotho were positive predictors of sclerostin

	– No correlation was found sclerostin and eGFR and CKD stages	NDA	
Hernandez et al. [37]	– 29 KTRs randomized to zoledronic acid (5 mg, iv at the time of kidney transplantation) plus cholecalciferol (25,000 UI every 15 days for 12 months) for 12 months (N 15), vs. only cholecalciferol at the same dose (N 14)

– Bone biopsies were performed at baseline (at the time of kidney transplantation) and after 12 months of treatment. control group comprising 29 age- and gender-matched iliac crest bone samples

– Histomorphometric evaluation was performed in bone and bone marrow adipocytes

– Sclerostin expression in osteocytes was evaluated by immunohistochemistry

– Serum sclerostin was determined by ELISA (TecoMedical)

	– Sclerostin levels were not decreased after kidney transplantation

– Osteocyte sclerostin expression after kidney transplantation decreased with the use of ZA compared to KTRs who only taking cholecalciferol

– Kidney transplantation fails to normalize bone marrow adiposity which are higher in kidney transplantation vs. healthy controls and even gets worse with the use of zoledronic acid

– There was inverse correlation between osteocyte sclerostin expression and bone marrow adiposity

	NDA	NDA	
Basir et al. [10]	– In 78 KTRs, serum sclerostin measured and lumbar and femoral neck bone mineral densities and T and Z scores were measured by DEXA in a cross-sectional study

– Patients with parathyroid adenoma or parathyroidectomy history were excluded

– Sclerostin measured by ELISA kit (Elabscience, Houston, TX, USA) on an enzyme-linked immunosorbent assay device (Thermo Fisher Scientific)

	– The osteoporotic group had lower sclerostin vs. non-osteoporotic group (405.9 vs. 521.7 ng/dl)

– SCL not correlated with cumulative corticosteroid dose, intact PTH, bone mineral density, and T scores

	– No relationship between eGFR and sclerostin	NDA	
Evenepoel et al. [24]	– In 518 adult KTRs bone mineral density measured at several skeletal sites within 14 days post-transplant and bone turnover markers are measured

– Serum sclerostin was determined with an ELISA (TecoMedical)

	– Baseline sclerostin levels were 2.21, 1.84, and 1.79 ng/l in normal, osteopenic, and osteoporotic patients (P 0.01)

– Baseline sclerostin was positively associated with FGF-23 and negatively with PTH and 1, 25D

– Baseline sclerostin levels with and without incident fracture were not different 2.08 ng/l [1.64–2.48] vs. 1.87 ng/l [1.30–2.67]

	NDA	NDA	
Marques et al. [25]	– In an open label, randomized trial, 17 KTRs assigned to Zoledronate (N 17) and control (N 17) before kidney transplantation

– Bone biopsy performed at the time of kidney transplantation and after 12 months to analyze bone histomorphometry

– DXA and high-resolution peripheral quantitative computed tomography performed in zolendronate group (N 16) and in controls (N 16) at the end of study

– Serum sclerostin was measured using ELISA (TecoMedical)

	– Serum sclerostin decreased after kidney transplantation (1.05 to 0.52 ng/ml) but no effect of Zoledronate was found on this parameter

– No significant correlations were seen between changes in serum sclerostin and changes in DXA, tomography bone histomorphometry

	NDA	NDA	
Araújo et al. [38]	– 31 Bone biopsy specimens obtained in KTRs who randomized to control or zoledronate groups for 1 year but data were shown for all patients

– Serum sclerostin was measured using ELISA (TecoMedical)

	– Sclerostin decreased after kidney transplantation

– No change in bone volume or mineralization occurred after kidney transplantation, however low bone turnover became more frequent after kidney transplantation ranging from 10 (32%) to 20 (65%)

– Bone expression of sclerostin and bone sclerostin increased, whereas serum sclerostin decreased after kidney transplantation suggesting sclerostin decrease is not due to a decrease in the bone osteocytic synthesis but due to improved renal function

	NDA	NDA	
Coban and Okten [19]	– The correlation between sclerostin and bone mineral density investigated in KTRs with more than 1 year after kidney transplantation

– 80 KTRs and 40 healthy controls included

– Serum sclerostin measured with (ELISA, Elabscience, CA, USA)

	– There was no difference in sclerostin levels between KTRs and healthy individuals

– High sclerostin associated with lower proximal femur bone mineral density

	– No significant correlation between sclerostin and eGFR	NDA	
Evenepoel et al. [39]	– 69 KTRs with steroid minimization immunosuppressive protocol underwent into a 5-year prospective observational study to evaluate changes in bone mineral density, mineral metabolism, and bone remodeling at baseline, 1 year after kidney transplantation and 5 year after kidney transplantation

– Serum sclerostin was measured using ELISA (TecoMedical)

	– Sclerostin significantly decreased 67.4% at first year after kidney transplantation from 2.217 to 0.74 ng/l but increased significantly at post-transplant 5 years to 0.88

– In femoral neck bone mineral density, as compared with losers, gainers were characterized by higher sclerostin 2.53 vs. 1.82 ng/l at 1 year but not different at 5 year

	NDA	NDA	
Zeng et al. [18]	– 600 stable KTRs were followed for 3 years which end-point is all-cause mortality

– Baseline blood and urine samples including sclerostin measured for analysis and clinical data were collected at study entry

– Sclerostin was measured with the use of a ELISA (Biomedica)

	– Non-survivors (n 65) had higher plasma sclerostin levels than survivors (N 535) (57.31 ± 30.28 pmol/l vs. 47.52 ± 24.87 pmol/l)	– In subgroup analysis sclerostin is an important all-cause mortality risk factor among patients with lower eGFR (< 44.41 ml/min/1.73 m2)	– In multiple Cox regression analysis, sclerostin was independent predictor of all-cause mortality (HR 1.011; 95% CI 1.002–1.020)	
Ferreira et al. [20]	– In 67 KTRs, sclerostin, densitometry (by DXA), bone histomorphometry (by biopsy), and CAC (by cardiac CT) performed 1 year after kidney transplantation

– Sclerostin was measured with the use of a ELISA (Biomedica)

	– Sclerostin after in year kidney transplantation was 0.7 (0.49–0.96) ng/ml

– High sclerostin associated with high bone mineral density both at spine and femur

	NDA	NDA	
Ferreira et al. [14]	– 84 KTRs prospectively followed for 12 months

– Demographic, clinical, and echocardiographic data were collected, laboratory evaluation, bone biopsy, and X-ray of the pelvis and hands were performed

– Patient and graft survival were recorded

– Vascular calcifications measured by through X-ray of the pelvis and hands by Adragão score

– Sclerostin was measured with the use of a ELISA (Biomedica)

	– Baseline sclerostin levels were elevated 1.9 (1.2–2.8) ng/ml

– Low bone turnover was associated with high levels of sclerostin

– Sclerostin levels were 2.2, 1.3, and 1.1 in low, normal, and high turnover bone disease

– Interdependently, high bone turnover was independently associated with lower sclerostin levels

– Isolated low bone volume was associated with higher levels of sclerostin (2.8 vs. 1.9 ng/Ml)

– Bone mineralization was not associated with sclerostin

	NDA	– In KTRs with mild score of Adragao vascular calcification score had lower sclerostin vs. higher scores

1.89 ± 0.9 vs. 2.45 ± 0.9 ng/ml suggesting high sclerostin was associated with vascular calcification

– Sclerostin was the only predictor of survival with higher levels had higher death (HR = 3.24, P = 0.041

– Sclerostin levels were not different between KTR with or without heart valve calcification (2.1 vs. 1.9 ng/ml)

	
Ferreira et al. [22]	– In 69 KTRs pre- and 1-year post-kidney transplantation clinical, biochemical, histological (bone biopsy), and imaging (echocardiography radiography of the pelvis and hands) parameters measured

– Sclerostin was measured with the use of a ELISA (Biomedica)

	– Sclerostin decreased in all KTRs after kidney transplantation (from 1.9 [1.3–2.7] ng/ml to 0.7 [0.5–1.0] ng/ml

– The impact of sclerostin was assessed on three bone associated changes namely: bone remodeling, bone volume, and bone mineralization

– In KTRs with decreased bone remodeling after kidney transplantation, sclerostin levels lower at 1 year after kidney transplantation vs. baseline (0.5 [0.3–0.9] ng/ml vs. 0.8 [0.6–1.0] ng/ml and a higher percentage reduction in sclerostin (68.9% versus 59.4%)

– In KTRs with bone volume loss, baseline sclerostin levels higher compared to KTRs without bone loss (2.5 [2.2–4] ng/ml vs. 1.7 [1.2–2.7] and a significant decrease and in sclerostin values from baseline (− 2.2 [− 3.1 to − 1.2] vs. − 1.1 [− 1.6 to 0.7]

– The decrease in bone volume after the kidney transplantation was associated with the highest levels of sclerostin at baseline

– Mineralization was not effected by sclerostin after kidney transplantation

	NDA	– Sclerostin levels higher in KTRs with higher CAC (by Agatston score)

– Baseline sclerostin in Agatston percentile ≤ 50%, 51–90%, and > 90% were 1.7, 2.1, and 2.2 (ng/ml) but not different at 1 year (0.6, 0.7, and 0.9 ng/Ml, respectively)

– In the multivariate analysis, baseline sclerostin was positively associated with CAC percentiles

	
Magalhães et al. [13]	– In 13 KTRs, the relationship between histomorphometric analysis with serum biomarkers analyzed prospectively

– Plasma sclerostin measured by ELISA (Biomedica)

	– Non-significant decrease of sclerostin at 12 months vs. baseline observed 1502 ± 201.4 pg/ml vs. 1307 ± 143.5 pg/ml

– At 18 months post-kidney transplantation sclerostin levels began to increase (1544 ± 287.8 pg/ml), being significantly higher at 24 months after kidney transplantation in comparison with the levels observed at 12 months (1307 ± 143.5 pg/ml at 12M vs. 2094 ± 318.6 pg/ml at 24M) after kidney transplantation

– Sclerostin did not correlate with calcium, phosphorus, vitamin D, PTH, FGF-23

- Sclerostin correlated significantly and positively with trabecular separation and negatively with trabecular number independent of calcium, phosphorus, intact PTH and plasma creatinine., both indicating that increased levels of this new biomarker is related to low bone volume

	NDA	NDA	
Koh et al. [17]	– In 591 KTRs, sclerostin measured before kidney transplantation and followed prospectively for 5 years

– Abdominal aortic calcification and brachial-ankle PWV measured at pre-transplant screening and 3 and 5 years after kidney transplantation

– Method for sclerostin measurement: Not reported

	– The median sclerostin level was 296.6 (226.8–404.5) pg/ml

– Serum PTH were inversely associated with sclerostin, whereas serum calcium, 25-D, and 1, 25-D levels were positively associated with sclerostin

	– The rejection was higher in the group with low sclerostin only for acute antibody-mediated rejection	– In linear regression analysis, higher sclerostin levels were associated with faster increase in post-transplant abdominal aortic calcification and PWV

– In multivariable analyses, 1% increase in sclerostin (98.1 [95% CI 18.8–177.3]) and the third tertile sclerostin levels (126.7 [95% CI 35.6–217.8]) were significantly associated with an increase in aortic PWV after KT

– Stroke events showed an increasing pattern of 0.5%, 1%, and 3% as the sclerostin levels increased from the first to the third tertile

	
Wang et al. [15]	– In 79 KTRs, circulating sclerostin, DKK1, FGF-23 and α-klotho arterial stiffness (carotid-femoral PWV), carotid-radial PWV, augmented index and bone parameters were assessed before (M0), and at 3 (M3) and 6 months (M6) after kidney transplantation	– Sclerostin at MO, M3, and M6 were (2.06 ± 1.18, 0.81 ± 0.24, and 0.88 ± 0.29 ng/ml, respectively

– The levels of sclerostin decreased at M3 and M6 vs. MO (not different between M3 vs. M6)

	NDA	– Sclerostin positively associated with carotid-femoral and carotid-radial PWV throughout the 6 months of follow-up

– The decrease of sclerostin and FGF-23 at M3 and M6 was associated with the decrease of cf-PWV and cr-PWV

	
Zuo et al. [60]	– In 531 stable KTRs the relationship between 25-D, 1, 25-D and iPTH, oxPTH n-oxPTH and sclerostin investigated

– Sclerostin measured by ELISA (TecoMedical)

	– Sclerostin levels were 50.61 ± 24.16 pg/ml

– Sclerostin levels negatively associated with 1,25-D but not with 25-D

– In multivariate analysis no associations between 25-D and 1, 25D were observed

	NDA	NDA	
Vigil et al. [113]	– Bone metabolism proteins including sclerostin measured in plasma in KTRs (n 57), hemodialysis patients (n 26), and healthy controls (n 31)

– Sclerostin measured by a Luminex-based microbead assay using a MAGPIX microsphere analyzer

	– Sclerostin levels were lower in KTRs vs. HD and control groups and no difference between control and HD

– In KTRs, sclerostin is positively correlated with DKK1 and osteoprotegerin and FGF-23

	NDA	NDA	
KTRs kidney transplant recipients, GFR glomerular filtration rate, NDA no data available, CKD chronic kidney disease, DKK1 Dickkopf-related protein 1, iPTH intact parathyroid hormone, PWV pulse wave velocity, CAC coronary artery calcification, AP Alkaline Phosphatase, FGF-23 Fibroblast Growth Factor 23, 25D 25-hydroxyvitamin, 1, 25D 1, 25-dihydroxyvitamin D

Relationship Between Sclerostin and Bone Parameters

We identified articles showing associations of sclerostin with PTH, fibroblast growth factor 23 (FGF-23), vitamin D, and klotho levels. With regard to PTH, sclerostin was shown to be either negatively associated with PTH [12, 17] or showed no association [13]. In general, sclerostin was positively associated with FGF-23 [9, 24]. The relationship between sclerostin and vitamin D is more complex. Sclerostin was correlated positively with 25 hydroxy vitamin D (25D) levels [9, 17] but correlated both positively [17] and negatively [9] with 1–25 hydroxy vitamin D levels (1-25D). Sclerostin was also positively correlated with klotho [9].

Relationship Between Sclerostin and Bone Mineralization Bone Turnover and Bone Volume

In KTRs, there are various studies investigating the relationship of sclerostin with bone mineralization, bone turnover, and bone volume. With regard to bone mineralization, some studies have shown that lower sclerostin levels were associated with lower bone mineral density [10, 20, 24] while other showed that high sclerostin was associated with low bone mineralization [19] and others showed no association [25]. Some studies documented associations of high sclerostin with low bone turnover [20]. Various studies have also shown associations of elevated sclerostin with low bone volume in KTRs [13, 14, 20, 22].

Relationship Between Sclerostin and Graft Function

With regard to graft function, some studies have shown negative associations between sclerostin and glomerular filtration rate, GFR [11, 12]. While others showed no association [9, 10, 23]. We did not identify any studies investigating the relationship between protein–albumin/creatinine ratio and sclerostin in KTR.

Relationship Between Sclerostin and Vascular Calcification and Cardiovascular Outcome

The studies regarding sclerostin and vascular calcification in KTRs were also inconsistent with some studies showing positive associations [14, 17, 22] while others studies showing negative associations [16]. Sclerostin has been also associated positively with arterial stiffness [11, 15, 17]. However, we did not find any study investigating the relationship between sclerostin and hard cardiovascular end points such as myocardial ınfarction, heart failure, stroke, and peripheral arterial disease in KTRs. Lastly, there are also studies showing that high sclerostin was associated with lower antibody-mediated allograft rejection [21] but higher mortality [18].

Discussion

Although kidney transplantation is the preferred treatment choice for end-stage kidney disease, long-term prognosis is hampered by chronic allograft failure due to many reasons and associated with long-term cardiovascular morbidity and mortality [2]. Thus, there is unmet need for new biomarkers to early detect and manage kidney dysfunction and cardiovascular events in KTRs. One of these potential but less studied marker in sclerostin in KTRs. As identified in this review, sclerostin was associated with laboratory, clinical, and bone-related parameters in KTRs with conflicting results. To frame these results, we briefly review current knowledge of physiology of sclerostin, then summarize sclerostin changes before and after kidney transplantation and its association with GFR. We also shed light regarding the association between sclerostin bone parameters, vascular calcification, and arterial stiffness. Lastly, we defined conflicting issues, and potential drawbacks of sclerostin measurement.

Sclerostin Physiology

Sclerostin is mainly synthetized in the bone by osteocytes and to a lesser extent by osteoclast precursors. The main action of sclerostin is to inhibit bone formation and mineralization by blocking osteoblast differentiation and function. At molecular level, the action of sclerostin is through wingless-related integration site (Wnt) signaling in the bone. Sclerostin binds to low density lipoprotein receptor-related proteins on cells of the osteocytes and inhibit the activity of Wnt/ß-catenin canonical signaling pathway. Sclerostin is one of the Wnt inhibitors blocks the extracellular binding of Wnt to transmembrane receptors complex thus preventing translocation beta-catenin to nucleus and subsequent gene expression. In murine knockout models, deficiency of sclerostin associated with high bone mass [26]. Sclerostin also impacts osteoblast maturation and decreases expression of osteoprotegerin (OPG) which promotes bone formation by mature osteoblasts. Thus sclerostin results in the decreased OPG and OPG/RANKL (the receptor activator of nuclear factor kappa-B ligand) ratio, which increases osteoclastic bone resorption [9, 27–29]. Mechanical stimulus or loading is also important for sclerostin synthesis which reduce osteocyte sclerostin generation. Reference [30] explaining the lowering impact of physical activity on sclerostin levels [31]. Reciprocally, in animal models, with unloaded bone, sclerostin levels increase dramatically. Furthermore, injection of sclerostin blocking antibodies in rats increases trabecular and cortical bone mass and induced a strong increase in bone formation rate [32]. A part from actions on bone, sclerostin has metabolic effects and higher sclerostin was associated with higher body mass index, fat mass, and insulin resistance [33]. Furthermore, sclerostin is thought to play a role in vascular calcification [34] and arterial stiffness [35] as discussed further below.

Sclerostin Levels, Kidney Transplantation, and Graft Function

There are various studies that measure sclerostin levels only before kidney transplantation (baseline) and only after kidney transplantation and both before and after kidney transplantation to catch up longitudinal changes. We found some studies showing that sclerostin decreased after kidney transplantation in the first weeks but then start to increase beginning at third month [12] or sixth month [23]. Other studies showed fluctuating sclerostin levels after kidney transplantation [15, 36]. In general, sclerostin appears to decrease after kidney transplantation [22, 25, 37–39] but there are also studies showing no difference of sclerostin before and after kidney transplantation [13]. Even in the same study, it was shown that despite increasing bone synthesis of sclerostin, circulating sclerostin has found to be decreased [38] suggesting that serum sclerostin does not necessarily reflect sclerostin levels in bone [40].

In this review, we found that sclerostin was either negatively associated with GFR or no association was found. In general, longitudinal studies measuring multiple sclerostin showed that sclerostin decreased in early period but increased thereafter beginning at month 3 [12], month 6 [23], and month 12 [13]. Why does this dynamic changes occur? Although the current answers are not known, some speculations can be made. First, sclerostin having a low molecular mass and positive charge can be filtered through glomerulus and in physiological conditions, most of this filtered sclerostin is reabsorbed in the proximal tubule [41]. However, in the early post-transplant period, proximal tubular dysfunction—which is most commonly related to ischemia–reperfusion injury—may induce overloading proteinuria resulting in the losses of substantial amounts of sclerostin in the urine resulting low plasma sclerostin [12]. Second, as sclerostin levels increase as GFR declines [42], it is possible that GFR restoration after kidney transplantation may be associated with lower sclerostin. However, others suggest that despite reductions in GFR, renal fractional excretion of sclerostin may increase up to 20 times and only moderate elevations of sclerostin occurs [43]. Third, despite lowering of PTH levels after kidney transplantation, this may take time and high PTH levels during early post-transplantation period may contribute to low sclerostin due to inhibitory effect of PTH on sclerostin [12, 44]. Fourth, high glucocorticoid use in early post-transplant period may suppress serum sclerostin levels, although prolonged treatment appears to be associated with increased serum sclerostin [45]. However, this issue is complex since in vitro studies showed that glucocorticoid administration to osteoblasts increased sclerostin production but mice treated with glucocorticoids exhibited decreased sclerostin expression [46]. In humans, the acute administration of glucocorticoids over a 96-h period induced a decrease in serum sclerostin, whereas long-term administration was associated with increased sclerostin levels at 12 months after therapy initiation in a dose-dependent fashion [47]. It was also suggested that the discordance between serum and bone sclerostin may be caused by glucocorticoid treatment [48, 49]. Fifth, the increase in physical activity in these patients after kidney transplantation may also help explain decrease of sclerostin [50]. Sixth, bone loss, which commonly occurs early after kidney transplantation [51] may be associated with low sclerostin.

Although all these hypotheses explain the reduction of sclerostin in the early post-transplant period, there is no satisfactory explanation for increase of sclerostin in the long-term period identified in some studies [13, 23]. One can assume that these changes are closely associated with changes in GFR but this is not the real case. For example, although Evenepoel et al. showed inverse association between sclerostin and GFR [12] Bonani et al. showed no association between GFR and sclerostin [23]. Thus, although GFR may impact the sclerostin levels; it should not be the only reason for elevation of sclerostin after kidney transplantation. Another alternative hypothesis is reduction of PTH after kidney transplantation in long term. As PTH levels inhibit sclerostin under physiologic conditions, lack of PTH inhibition potentially elevates sclerostin in non-early period of kidney transplantation. Lastly, as high sclerostin levels also reflect increased osteocyte number and skeletal mass [52, 53]; the increase in sclerostin after kidney transplantation may simply reflect increased bone mass after kidney transplantation. Indeed, although bone loss and fractures are common in the early post-kidney transplantation period, in long-term kidney transplantation patients bone mineral density improves progressively as time after kidney transplantation increased [54]. Based on these findings, the sclerostin trajectories after kidney transplantation are not uniform and complex and multiple etiologies play a role for final sclerostin levels (Fig. 2). Again, it is of note that circulating sclerostin levels may not reflect bone sclerostin at the site of clinical important action.Fig. 2 The dynamic changes of sclerostin after kidney transplantation. It is generally shown that, circulating sclerostin levels decrease after early kidney transplantation but then rebound increase occurred as the duration of kidney transplantation increased although the elevation of sclerostin after KT occurred at different intervals beginning from 3 to 12 months. Even though the exact mechanisms of this dynamic changes are unclear, potentially different factors impact circulating sclerostin levels at the early and late phase after KT

Association of Sclerostin with Bone Parameters, Bone Histomorphometry, Bone Mass, Bone Mineralization, and Kidney Transplantation

The MBD pathology is very complex, involving various parameters such as bone-related clinical parameters (calcium, phosphorus, PTH, vitamin D, bone-specific alkaline phosphatase FGF-23, klotho), bone mineralization, bone turnover, and bone mass. In kidney transplantation, there are no specific studies investigating the reciprocal changes between calcium-sclerostin and phosphorus-SCL. The relationship between sclerostin and phosphorus was a complex issue and not fully elucidated. While sclerostin levels were associated with phosphorus levels in hemodialysis patients [55], a recent study demonstrated that a treatment with an anti-sclerostin antibody reduced serum levels of intact FGF-23 and increased serum phosphate levels [56]. This difference may be due to fact that in hemodialysis patients despite increased FGF-23 levels phosphate cannot be excreted due to oliguria/anuria. Furthermore, although the regulation of FGF-23 by sclerostin is suggested to be indirect and mediated by the control of bone turnover [57], a cell study using the osteocytic cell line IDG-SW3 suggested the direct stimulating effects of sclerostin on the synthesis of FGF-23 [58]. These issues are not studies in KTRs and subject to future investigation.

With regard to PTH, sclerostin was shown to be either negatively associated with PTH [12, 17] or showed no association [13]. The relationship between sclerostin and PTH seems to be dependent on pattern of PTH secretion. For example, circadian but not continuous increases in PTH have anabolic effects on bone partly due to activation of osteocyte PTH receptors which downregulate sclerostin expression [59]. Therefore, anabolic effects caused by a reduction in sclerostin may only occur by intermittent rise in PTH. Sclerostin was correlated positively with 25D [9, 17] and correlated either positively [17] or negatively [9, 60] with 1-25D. These findings may be explained by the interdependent relationship between vitamin D and sclerostin. Higher circulating 25D by resulting in higher intracellular 1, 25D which in turn, favor sclerostin synthesis by osteocytes. However, increased sclerostin levels exert a negative feed-back on 1, 25D synthesis [9]. Studies are also present showing that sclerostin was positively correlated with klotho [9] and with FGF-23 [9, 24] Indeed, it is known that sclerostin increases FGF-23 by inhibiting PHEX (phosphate regulating endopeptidase X-linked) [61] which stimulates FGF-23 degradation [62] thus reducing its activity.

With regard to association of bone volume, bone mineralization, and bone turnover with sclerostin, there were diverse and contrasting findings identified in the current review. The reasons for this discordant findings are not known but there are two opposite opinions: The first is compatible with the normal physiologic function of sclerostin which is to inhibit bone formation by blocking Wnt signaling and bone formation [63]. Other opinion suggest that high sclerostin levels reflect increased osteocyte number and increased skeletal mass [52, 53]. To combine these two opinions one may hypothesize that there may be a feedback regulation during bone hemostasis that is when bone formation increased, sclerostin also increased which then decrease bone formation by suppressing Wnt signaling and normalizing increased bone formation (Fig. 3). Whether this hypothesis holds true especially in kidney transplantation needs further investigation. However, it is clear that romosozumab—a humanized monoclonal antibody sclerostin inhibitor- increased bone mass in healthy men and postmenopausal women with low bone mass [64]. Furthermore, higher levels of sclerostin was associated with increased fracture risk [65, 66]. It was also shown that postmenopausal women with osteoporosis, romosozumab was associated with a lower risk of vertebral fracture than placebo [67]. In patients receiving hemodialysis treatment romosozumab increased bone mineral density without increased cardiovascular events [68]. However, it was suggested that romosozumab may be associated with increased cardiovascular events and should not be used in patients with a recent cardiovascular event and should be used cautiously in patients with high cardiovascular risk [69]. To date there is no study investigating the role of romosozumab in KTRs.Fig. 3 Relationship between sclerostin and bone. When bone synthesis increases, expression of bone sclerostin increases by expanding osteocyte number. Sclerostin in turn decrease 1, 25-dihydroxyvitamin D and wingless-related Wnt). Simultaneously, increased sclerostin also increase FGF-23 and also (RANK/RANKL signaling which promotes bone resorption as a negative feedback to normalize increased bone formation. Wnt wingless-related integration site, FGF-23 Fibroblast Growth Factor 23, RANK receptor activator of NF-Κb, RANKL Ligand for RANK

Sclerostin Vascular Calcification, Arterial Stiffness, and Kidney Transplantation

Vascular calcifications (VC) are highly prevalent in KTRs which are associated with an increased risk of cardiovascular events and long-term mortality [70]. Vascular calcification is not passive but an active process which shares many features with bone formation [71]. During VC, a complex interplay of variety of molecules and signaling pathways occurs. The small integrin-binding ligand N-linked glycoprotein (SIBLING) family proteins including osteopontin, bone sialoprotein, [72, 73], osteoprotegerin [74], high phosphate and low pyrophosphate [75] all play role. Among signaling pathways bone morphogenetic protein and Runt‐related transcription factor 2 signaling, AMP‐activated protein kinase signaling pathway, The phosphatidylinositol 3‐kinase (PI3K)-AKT signaling pathway, NOTCH signaling pathway, Wnt-β-catenin signaling all play a role for VC [76]. Among these processes the role of sclerostin in VC is mostly associated with Wnt-β-catenin signaling. During VC, vascular smooth muscle cells undergo osteogenic dedifferentiation, which goes along with increased activation of the Wnt/β-catenin signaling cascade [77]. Overall, in the vessel wall, Wnt-β-catenin signaling promotes atherosclerosis and VC. However, in contrast, expression of Wnt antagonists in calcifying vascular smooth muscle cells increases which include sclerostin [78, 79]. An in vitro study showed that vascular smooth muscle cells undergo terminal trans-differentiation into an osteocyte-like cell type with sclerostin expression during calcification [78] suggesting that sclerostin actively play a role in this process. Additionally, the elevated sclerostin expression in calcifying aortic tissue was found in an in vitro model of uremic vasculopathy [80]. During in vivo models of acute kidney injury [81] and CKD [82] vascular (aortic) expression of sclerostin was also increased. This evidence suggests that increased sclerostin may be involved in development of VC and arterial stiffness.

Studies in KTRs demonstrated that sclerostin was positively associated with VC [11, 14, 15, 17, 22]. On the contrary, other suggest that sclerostin does not have facilitative role in the VC but has a protective role and sclerostin expression represents a counter regulatory mechanism aimed to suppress the progression of VC. This also aligns with the physiological role of sclerostin that is, the downregulation of matrix mineralization. In vitro studies also showed that sclerostin was able to suppress vascular smooth muscle cell osteoblastic differentiation [83, 84]. Based in this opinion, sclerostin produced in the calcified vessels protects vessel wall from further calcification and the produced sclerostin by vessel wall may spill-over to the serum compartment, leading to increased serum sclerostin levels in patients or animals with vascular media calcification [85, 86]. Thus non-skeletal (vascular) production of sclerostin in fact reflect a protective mechanisms against VC which contribute to the high circulating sclerostin levels in patients with advanced CKD [87]. To further ratify this hypothesis, in CKD-induced VC sclerostin knock-out mice showed more VC in cardiac vessels. Moreover, same study showed that in warfarin induced VC without CKD, DBA/2J mice showed more vascular calcification with anti-sclerostin antibody treatment suggesting a protective effect of sclerostin during VC [88].

It is of note that a bone biopsy study showed that increased circulating sclerostin levels in the elderly were not accompanied by an increase in sclerostin mRNA levels in bone, fueling the hypothesis that the contribution of non-skeletal sources, including the vasculature, to circulating levels may be relevant [89]. In KTRs, a study showed that baseline sclerostin level was inversely associated with progression of abdominal aortic and coronary artery calcifications in a multivariable model but after adjusting for baseline calcification score, the significance was lost [16]. Thus it is important to determine whether systemic levels of sclerostin play a causal role in the development of vascular calcifications or whether sclerostin production simply reflects phenotypic changes in the vessel walls as a protective negative feedback (Fig. 4). This is important issue, since if the second opinion is true and if sclerostin was actively inhibiting VC, the inhibition of sclerostin would be detrimental by promoting further VC in the vessel wall [26].Fig. 4 Sclerostin and vascular calcification. Vascular calcification is an active process which involves the transdedifferentiation of vascular smooth muscle cells into osteocyte-like cells. These differentiated cells secrete sclerostin. The literature regarding vascular calcification is conflicting. It was found that sclerostin is associated with positively and actively in vascular calcification process. On the other hand others proposed that sclerostin is protective against vascular calcification and the increased sclerostin supress vascular smooth muscle transdedifferentiation into osteocytes thus decreasing vascular calcification as a negative feedback. Although which hypothesis is true is not known currently, both of them suggest that increased bone sclerostin expression occurs during vascular calcification which spill over to circulation and effect bone metabolisms as a bone–vascular cross-talk

This calcification paradox is also important when sclerostin produced from the calcified vasculature spills into the circulation, it inhibits bone formation and consequently inhibits the ability of the bone to buffer calcium and phosphorus, allowing them to be deposited on the vascular walls [17]. Indeed, a recent study showed that when uremic aorta from a rat with CKD was transplanted into an animal with healthy kidney, the bone mineral density of the (otherwise healthy) recipient animal decreased, by impaired mineralization of bone. Additionally, the expression of sclerostin in bone increased in the recipient animals [90]. This study confirms the notion that bone-vascular axis in CKD is bidirectional and is not a “one-way route.” In KTRs, some studies have also shown that arterial stiffness was associated with arterial stiffness measured by pulse wave velocity, PWV [11, 17]. As PWV is also a strong predictor of cardiovascular events and all-cause mortality in transplant patients [91, 92], sclerostin levels before kidney transplantation would help with risk stratification by predicting deterioration of arterial stiffness after kidney transplantation [93, 94]. Future studies are needed to determine whether associations with surrogate measures such as vascular stiffness translate to differences in clinically important cardiovascular outcomes.

Areas of Uncertainty

The relationship with sclerostin, and graft function, bone and VC is not only complex but also conflicting in KTRs. One of the potential reasons for conflicting findings is the heterogeneity of studies with respect to sclerostin measurement (baseline, after or longitudinal measurement of sclerostin), population characteristics, glucocorticoid exposure etc. These conflicting data may be explained by case-mix, and different factors used in multivariate analysis. Moreover, the relationship may not be linear, but U-shaped [79]. Second, the difference between sclerostin assays may be of importance. Although commercially available sclerostin assays show good correlations between each other, they demonstrate significantly different results in terms of absolute sclerostin concentrations in serum. Therefore, studies using different sclerostin assays cannot be compared directly [50, 95, 96]. Delanaye et al. compared four different assays for measurement of sclerostin namely Biomedica, TecoMedical, R&D Meso Scale Discovery in 39 prevalent dialysis patients and 82 non-dialysis patients. observed large differences in median sclerostin concentrations (in pg/ml) and the concordance correlation coefficient between assays was poor. Sclerostin measured by Biomedica and TecoMedical, were negatively correlated with GFR which is not observed when sclerostin measured by Meso Scale Discovery and R&D. The associations between sclerostin and gender age, or parathormone were also different according to the assay used [97]. This is a clinically important limitation in comparing studies and it will be probably more important in the setting of kidney transplantation which GFR can fluctuate.

The relationship between sclerostin and mortality in kidney transplantation also deserves mention. Studies evaluating the association between circulating sclerostin levels and mortality in CKD have yielded inconsistent results, with some investigators reporting high circulating sclerostin levels to associate with better survival [85, 98] and other investigators reporting an inverse [99] or no association [100, 101]. In KTRs, one study reported that sclerostin was positively associated with mortality in KTRs [18]. More studies are needed to highlight the relationship between sclerostin and mortality in kidney transplantation, as well as clinically relevant outcomes such as major adverse cardiovascular events. Lastly, whether metabolic actions of sclerostin (fat metabolism, insulin resistance etc.) impacts graft function and cardiovascular events needs further assessment.

The inhibitory role of sclerostin in bone formation is well known, but is also suggested that increased bone as reflected by increased osteocyte number also increase sclerostin synthesis. Furthermore, skeletal heterogeneity of sclerostin expression is probable, reflecting differences in mechanical loading between different skeletal sites [102]. Acute high doses of glucocorticoids or cumulative doses of glucocorticoids may also shape the relationship between sclerostin and bone in KTRs. As with other issues, the role of sclerostin on VC is not straightforward. Two hypotheses were postulated two explain the diverge findings regarding vascular calcification. One is suggesting sclerostin plays a direct (stimulating) role in VC and the other hypothesis suggest protective effect of sclerostin on vascular calcification were explained above (Fig. 4). Other potential explanations for these diverge findings include the heterogeneity of VC at different anatomical locations which may lead to different results regarding the association between sclerostin and the measured vascular outcomes. This vascular anatomy specific association is supported by studies reporting differences in the local expression of sclerostin depending on the anatomical location of blood vessels [103, 104]. Assuming that sclerostin has a similar role in the vascular wall as in bone (i.e., decreasing mineralization), blockage of sclerostin potentially stimulates mineralization, hence promoting VC in the vessel wall which should be treated as a warning signal [26]. Indeed, inhibition of sclerostin with romosozumab for treatment of osteoporosis showed increased cardiovascular risk although treated patients were older and take more cardiovascular medication (anticoagulants, antiplatelet agents, antihypertensives) and therefore were probably more likely to have cardiovascular events at baseline [105]. In stable coronary heart disease patients, high sclerostin increased all-cause mortality risk [106]. In patients receiving hemodialysis (HD) treatment, high sclerostin levels presented a trend toward higher risk for cardiovascular mortality [107]. On the other hand, in end-stage renal disease patients receiving treatment with HD or hemodiafiltration low sclerostin levels were associated with higher symptoms of coronary heart disease and rhythm disturbance [108]. Studies are also present showing that high sclerostin levels was found in patients with stroke compared to health controls [109, 110].

In KTRs, no data regarding safety of romosozumab is available. Thus the particular role of sclerostin specifically in VC and kidney transplantation requires further investigation [111]. Lastly, it needs to be determined whether there is interrelationship between acute rejection episodes and sclerostin levels [21].

Conclusion

Sclerostin is an important molecule MBD. In KTRs, various studies have shown that sclerostin is associated with graft function, bone parameters, vascular calcification, and arterial stiffness although non-uniformly. However, we did not find any specific study investigating the relationship between sclerostin and hard cardiovascular outcomes such as myocardial infarction, heart failure, stroke or peripheral arterial disease in KTRs. Thus, although sclerostin has potential to be a marker of risk stratification in KTR, more studies including movement to surrogate to clinical outcomes are needed to determine if sclerostin has can be used as a clinically actionable marker of BM-CKD in KTRs. Specifically, large-scale prospective studies are needed to evaluate the impact of sclerostin on CKD–MBD and whether sclerostin can be used to monitor treatment response in BMD and cardiovascular disease in KTRs. This is important since performed studies are mostly observational and not interventional and the cause and effect relationship cannot be inferred. Moreover, it needs to be clarified whether inhibition of sclerostin as a clinical strategy in KTRs is feasible or the effects of such intervention increases cardiovascular risk.

Acknowledgements

Figures are generated by Biorender.com.

Author Contributions

Concept and literature search was performed by Baris Afsar. All authors contributed to the manuscript, revised the paper critically for intellectual content and have approved the final draft.

Funding

Open access funding provided by the Scientific and Technological Research Council of Türkiye (TÜBİTAK).

Data Availability

No new data were created or analyzed in this review.

Declarations

Conflict of interest

Baris Afsar, Rengin Elsurer Afsar, Yasar Caliskan, and Krista L. Lentine declare that they have no conflict of interest to disclose.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Tonelli M Wiebe N Knoll G Bello A Browne S Jadhav D Klarenbach S Gill J Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes Am J Transplant 2011 11 10 2093 2109 10.1111/j.1600-6143.2011.03686.x 21883901
Tonelli M, Wiebe N, Knoll G, Bello A, Browne S, Jadhav D, Klarenbach S, Gill J (2011) Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant 11(10):2093–2109. 10.1111/j.1600-6143.2011.03686.x21883901 10.1111/j.1600-6143.2011.03686.x
2. Thongprayoon C Hansrivijit P Leeaphorn N Acharya P Torres-Ortiz A Kaewput W Kovvuru K Kanduri SR Bathini T Cheungpasitporn W Recent advances and clinical outcomes of kidney transplantation J Clin Med 2020 10.3390/jcm9041193 32846935
Thongprayoon C, Hansrivijit P, Leeaphorn N, Acharya P, Torres-Ortiz A, Kaewput W, Kovvuru K, Kanduri SR, Bathini T, Cheungpasitporn W (2020) Recent advances and clinical outcomes of kidney transplantation. J Clin Med. 10.3390/jcm904119332846935 10.3390/jcm9041193
3. KDIGO CKD–MBD Update Work Group KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) Kidney Int Suppl (2011) 2017 7 1 1 59 10.1016/j.kisu.2017.04.001 30675420
KDIGO CKD–MBD Update Work Group (2017) KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl (2011) 7(1):1–59. 10.1016/j.kisu.2017.04.00130675420 10.1016/j.kisu.2017.04.001
4. Moe S Drüeke T Cunningham J Goodman W Martin K Olgaard K Ott S Sprague S Lameire N Eknoyan G Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) Kidney Int 2006 69 11 1945 1953 10.1038/sj.ki.5000414 16641930
Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69(11):1945–1953. 10.1038/sj.ki.500041416641930 10.1038/sj.ki.5000414
5. Mace ML Egstrand S Morevati M Olgaard K Lewin E New insights to the crosstalk between vascular and bone tissue in chronic kidney disease–mineral and bone disorder Metabolites 2021 10.3390/metabo11120849 34940607
Mace ML, Egstrand S, Morevati M, Olgaard K, Lewin E (2021) New insights to the crosstalk between vascular and bone tissue in chronic kidney disease–mineral and bone disorder. Metabolites. 10.3390/metabo1112084934940607 10.3390/metabo11120849
6. Vangala C Pan J Cotton RT Ramanathan V Mineral and bone disorders after kidney transplantation Front Med (Lausanne) 2018 5 211 10.3389/fmed.2018.00211 30109232
Vangala C, Pan J, Cotton RT, Ramanathan V (2018) Mineral and bone disorders after kidney transplantation. Front Med (Lausanne) 5:211. 10.3389/fmed.2018.0021130109232 10.3389/fmed.2018.00211
7. Evenepoel P Naesens M Claes K Kuypers D Vanrenterghem Y Tertiary ‘hyperphosphatoninism’ accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients Am J Transplant 2007 7 5 1193 1200 10.1111/j.1600-6143.2007.01753.x 17359508
Evenepoel P, Naesens M, Claes K, Kuypers D, Vanrenterghem Y (2007) Tertiary ‘hyperphosphatoninism’ accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 7(5):1193–1200. 10.1111/j.1600-6143.2007.01753.x17359508 10.1111/j.1600-6143.2007.01753.x
8. Figurek A Rroji M Spasovski G Sclerostin: a new biomarker of CKD–MBD Int Urol Nephrol 2020 52 1 107 113 10.1007/s11255-019-02290-3 31612420
Figurek A, Rroji M, Spasovski G (2020) Sclerostin: a new biomarker of CKD–MBD. Int Urol Nephrol 52(1):107–113. 10.1007/s11255-019-02290-331612420 10.1007/s11255-019-02290-3
9. Tartaglione L Pasquali M Rotondi S Muci ML Leonangeli C Farcomeni A Fassino V Mazzaferro S Interactions of sclerostin with FGF23, soluble klotho and vitamin D in renal transplantation PLoS ONE 2017 12 5 e0178637 10.1371/journal.pone.0178637 28558021
Tartaglione L, Pasquali M, Rotondi S, Muci ML, Leonangeli C, Farcomeni A, Fassino V, Mazzaferro S (2017) Interactions of sclerostin with FGF23, soluble klotho and vitamin D in renal transplantation. PLoS ONE 12(5):e0178637. 10.1371/journal.pone.017863728558021 10.1371/journal.pone.0178637
10. Basir H Altunoren O Erken E Kilinc M Sarisik FN Isiktas S Gungor O Relationship between osteoporosis and serum sclerostin levels in kidney transplant recipients Exp Clin Transplant 2019 10.6002/ect.2019.0022 31526333
Basir H, Altunoren O, Erken E, Kilinc M, Sarisik FN, Isiktas S, Gungor O (2019) Relationship between osteoporosis and serum sclerostin levels in kidney transplant recipients. Exp Clin Transplant. 10.6002/ect.2019.002231526333 10.6002/ect.2019.0022
11. Hsu BG Liou HH Lee CJ Chen YC Ho GJ Lee MC Serum sclerostin as an independent marker of peripheral arterial stiffness in renal transplantation recipients: a cross-sectional study Medicine (Baltim) 2016 95 15 e3300 10.1097/md.0000000000003300
Hsu BG, Liou HH, Lee CJ, Chen YC, Ho GJ, Lee MC (2016) Serum sclerostin as an independent marker of peripheral arterial stiffness in renal transplantation recipients: a cross-sectional study. Medicine (Baltim) 95(15):e3300. 10.1097/md.000000000000330010.1097/md.0000000000003300
12. Evenepoel P Claes K Viaene L Bammens B Meijers B Naesens M Sprangers B Kuypers D Decreased circulating sclerostin levels in renal transplant recipients with persistent hyperparathyroidism Transplantation 2016 100 10 2188 2193 10.1097/tp.0000000000001311 27379556
Evenepoel P, Claes K, Viaene L, Bammens B, Meijers B, Naesens M, Sprangers B, Kuypers D (2016) Decreased circulating sclerostin levels in renal transplant recipients with persistent hyperparathyroidism. Transplantation 100(10):2188–2193. 10.1097/tp.000000000000131127379556 10.1097/tp.0000000000001311
13. Magalhães J Quelhas-Santos J Pereira L Neto R Castro-Ferreira I Martins S Frazão JM Carvalho C Could bone biomarkers predict bone turnover after kidney transplantation? A proof-of-concept study J Clin Med 2022 10.3390/jcm11020457 35054152
Magalhães J, Quelhas-Santos J, Pereira L, Neto R, Castro-Ferreira I, Martins S, Frazão JM, Carvalho C (2022) Could bone biomarkers predict bone turnover after kidney transplantation? A proof-of-concept study. J Clin Med. 10.3390/jcm1102045735054152 10.3390/jcm11020457
14. Ferreira AC Cotovio P Aires I Mendes M Navarro D Silva C Caeiro F Salvador R Correia B Cabral G Nolasco F Ferreira A The role of bone volume, FGF23 and sclerostin in calcifications and mortality; a cohort study in CKD stage 5 patients Calcif Tissue Int 2022 110 2 215 224 10.1007/s00223-021-00910-8 34477944
Ferreira AC, Cotovio P, Aires I, Mendes M, Navarro D, Silva C, Caeiro F, Salvador R, Correia B, Cabral G, Nolasco F, Ferreira A (2022) The role of bone volume, FGF23 and sclerostin in calcifications and mortality; a cohort study in CKD stage 5 patients. Calcif Tissue Int 110(2):215–224. 10.1007/s00223-021-00910-834477944 10.1007/s00223-021-00910-8
15. Wang YP Sidibé A Fortier C Desjardins MP Ung RV Kremer R Agharazii M Mac-Way F Wnt/β-catenin pathway inhibitors, bone metabolism and vascular health in kidney transplant patients J Nephrol 2023 36 4 969 978 10.1007/s40620-022-01563-y 36715822
Wang YP, Sidibé A, Fortier C, Desjardins MP, Ung RV, Kremer R, Agharazii M, Mac-Way F (2023) Wnt/β-catenin pathway inhibitors, bone metabolism and vascular health in kidney transplant patients. J Nephrol 36(4):969–978. 10.1007/s40620-022-01563-y36715822 10.1007/s40620-022-01563-y
16. Evenepoel P Goffin E Meijers B Kanaan N Bammens B Coche E Claes K Jadoul M Sclerostin serum levels and vascular calcification progression in prevalent renal transplant recipients J Clin Endocrinol Metab 2015 100 12 4669 4676 10.1210/jc.2015-3056 26505822
Evenepoel P, Goffin E, Meijers B, Kanaan N, Bammens B, Coche E, Claes K, Jadoul M (2015) Sclerostin serum levels and vascular calcification progression in prevalent renal transplant recipients. J Clin Endocrinol Metab 100(12):4669–4676. 10.1210/jc.2015-305626505822 10.1210/jc.2015-3056
17. Koh HB Ryu JH Kim SS Kim MG Park JB Kim CD Kang KP Ro H Han SY Huh KH Yang J Association between sclerostin levels and vascular outcomes in kidney transplantation patients J Nephrol 2023 36 7 2091 2109 10.1007/s40620-023-01732-7 37751127
Koh HB, Ryu JH, Kim SS, Kim MG, Park JB, Kim CD, Kang KP, Ro H, Han SY, Huh KH, Yang J (2023) Association between sclerostin levels and vascular outcomes in kidney transplantation patients. J Nephrol 36(7):2091–2109. 10.1007/s40620-023-01732-737751127 10.1007/s40620-023-01732-7
18. Zeng S Slowinski T Pommer W Hasan AA Gaballa MMS Lu Y Krämer BK Hocher B Sclerostin is an independent risk factor for all-cause mortality in kidney transplant recipients Clin Exp Nephrol 2020 24 12 1177 1183 10.1007/s10157-020-01956-y 32816133
Zeng S, Slowinski T, Pommer W, Hasan AA, Gaballa MMS, Lu Y, Krämer BK, Hocher B (2020) Sclerostin is an independent risk factor for all-cause mortality in kidney transplant recipients. Clin Exp Nephrol 24(12):1177–1183. 10.1007/s10157-020-01956-y32816133 10.1007/s10157-020-01956-y
19. Coban M Okten S The correlation between sclerostin and bone mineral density in renal transplant recipients Nefrologia (Engl Ed) 2020 40 5 506 513 10.1016/j.nefro.2020.04.009 32896441
Coban M, Okten S (2020) The correlation between sclerostin and bone mineral density in renal transplant recipients. Nefrologia (Engl Ed) 40(5):506–513. 10.1016/j.nefro.2020.04.00932896441 10.1016/j.nefro.2020.04.009
20. Ferreira AC Mendes M Silva C Cotovio P Aires I Navarro D Caeiro F Salvador R Correia B Cabral G Nolasco F Ferreira A Bone densitometry versus bone histomorphometry in renal transplanted patients: a cross-sectional study Transplant Int 2021 34 6 1065 1073 10.1111/tri.13888
Ferreira AC, Mendes M, Silva C, Cotovio P, Aires I, Navarro D, Caeiro F, Salvador R, Correia B, Cabral G, Nolasco F, Ferreira A (2021) Bone densitometry versus bone histomorphometry in renal transplanted patients: a cross-sectional study. Transplant Int 34(6):1065–1073. 10.1111/tri.1388810.1111/tri.13888
21. Venner JM Hidalgo LG Famulski KS Chang J Halloran PF The molecular landscape of antibody-mediated kidney transplant rejection: evidence for NK involvement through CD16a Fc receptors Am J Transplant 2015 15 5 1336 1348 10.1111/ajt.13115 25787894
Venner JM, Hidalgo LG, Famulski KS, Chang J, Halloran PF (2015) The molecular landscape of antibody-mediated kidney transplant rejection: evidence for NK involvement through CD16a Fc receptors. Am J Transplant 15(5):1336–1348. 10.1111/ajt.1311525787894 10.1111/ajt.13115
22. Ferreira AC Mendes M Silva C Cotovio P Aires I Navarro D Caeiro F Ramos R Salvador R Correia B Cabral G Nolasco F Ferreira A Improvement of mineral and bone disorders after renal transplantation Transplantation 2022 106 5 e251 e261 10.1097/tp.0000000000004099 35266925
Ferreira AC, Mendes M, Silva C, Cotovio P, Aires I, Navarro D, Caeiro F, Ramos R, Salvador R, Correia B, Cabral G, Nolasco F, Ferreira A (2022) Improvement of mineral and bone disorders after renal transplantation. Transplantation 106(5):e251–e261. 10.1097/tp.000000000000409935266925 10.1097/tp.0000000000004099
23. Bonani M Rodriguez D Fehr T Mohebbi N Brockmann J Blum M Graf N Frey D Wüthrich RP Sclerostin blood levels before and after kidney transplantation Kidney Blood Press Res 2014 39 4 230 239 10.1159/000355781 25118597
Bonani M, Rodriguez D, Fehr T, Mohebbi N, Brockmann J, Blum M, Graf N, Frey D, Wüthrich RP (2014) Sclerostin blood levels before and after kidney transplantation. Kidney Blood Press Res 39(4):230–239. 10.1159/00035578125118597 10.1159/000355781
24. Evenepoel P Claes K Meijers B Laurent MR Bammens B Naesens M Sprangers B Pottel H Cavalier E Kuypers D Bone mineral density, bone turnover markers, and incident fractures in de novo kidney transplant recipients Kidney Int 2019 95 6 1461 1470 10.1016/j.kint.2018.12.024 30922664
Evenepoel P, Claes K, Meijers B, Laurent MR, Bammens B, Naesens M, Sprangers B, Pottel H, Cavalier E, Kuypers D (2019) Bone mineral density, bone turnover markers, and incident fractures in de novo kidney transplant recipients. Kidney Int 95(6):1461–1470. 10.1016/j.kint.2018.12.02430922664 10.1016/j.kint.2018.12.024
25. Marques IDB Araújo M Graciolli FG Dos Reis LM Pereira RMR Alvarenga JC Custódio MR Jorgetti V Elias RM Moysés RMA David-Neto E A randomized trial of zoledronic acid to prevent bone loss in the first year after kidney transplantation J Am Soc Nephrol 2019 30 2 355 365 10.1681/asn.2018060656 30606784
Marques IDB, Araújo M, Graciolli FG, Dos Reis LM, Pereira RMR, Alvarenga JC, Custódio MR, Jorgetti V, Elias RM, Moysés RMA, David-Neto E (2019) A randomized trial of zoledronic acid to prevent bone loss in the first year after kidney transplantation. J Am Soc Nephrol 30(2):355–365. 10.1681/asn.201806065630606784 10.1681/asn.2018060656
26. Brandenburg VM Verhulst A Babler A D'Haese PC Evenepoel P Kaesler N Sclerostin in chronic kidney disease-mineral bone disorder think first before you block it! Nephrol Dial Transplant 2019 34 3 408 414 10.1093/ndt/gfy129 29846712
Brandenburg VM, Verhulst A, Babler A, D’Haese PC, Evenepoel P, Kaesler N (2019) Sclerostin in chronic kidney disease-mineral bone disorder think first before you block it! Nephrol Dial Transplant 34(3):408–414. 10.1093/ndt/gfy12929846712 10.1093/ndt/gfy129
27. Elder GJ Decreased circulating sclerostin levels in renal transplant recipients with persistent hyperparathyroidism: who's conducting the orchestra? Transplantation 2016 100 10 2016 2017 10.1097/tp.0000000000001312 27467532
Elder GJ (2016) Decreased circulating sclerostin levels in renal transplant recipients with persistent hyperparathyroidism: who’s conducting the orchestra? Transplantation 100(10):2016–2017. 10.1097/tp.000000000000131227467532 10.1097/tp.0000000000001312
28. Wijenayaka AR Kogawa M Lim HP Bonewald LF Findlay DM Atkins GJ Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway PLoS ONE 2011 6 10 e25900 10.1371/journal.pone.0025900 21991382
Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ (2011) Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS ONE 6(10):e25900. 10.1371/journal.pone.002590021991382 10.1371/journal.pone.0025900
29. Bennett CN Longo KA Wright WS Suva LJ Lane TF Hankenson KD MacDougald OA Regulation of osteoblastogenesis and bone mass by Wnt10b Proc Natl Acad Sci USA 2005 102 9 3324 3329 10.1073/pnas.0408742102 15728361
Bennett CN, Longo KA, Wright WS, Suva LJ, Lane TF, Hankenson KD, MacDougald OA (2005) Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci USA 102(9):3324–3329. 10.1073/pnas.040874210215728361 10.1073/pnas.0408742102
30. Pietrzyk B Smertka M Chudek J Sclerostin: intracellular mechanisms of action and its role in the pathogenesis of skeletal and vascular disorders Adv Clin Exp Med 2017 26 8 1283 1291 10.17219/acem/68739 29264888
Pietrzyk B, Smertka M, Chudek J (2017) Sclerostin: intracellular mechanisms of action and its role in the pathogenesis of skeletal and vascular disorders. Adv Clin Exp Med 26(8):1283–1291. 10.17219/acem/6873929264888 10.17219/acem/68739
31. Amrein K Amrein S Drexler C Dimai HP Dobnig H Pfeifer K Tomaschitz A Pieber TR Fahrleitner-Pammer A Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults J Clin Endocrinol Metab 2012 97 1 148 154 10.1210/jc.2011-2152 21994959
Amrein K, Amrein S, Drexler C, Dimai HP, Dobnig H, Pfeifer K, Tomaschitz A, Pieber TR, Fahrleitner-Pammer A (2012) Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endocrinol Metab 97(1):148–154. 10.1210/jc.2011-215221994959 10.1210/jc.2011-2152
32. Bouquegneau A Evenepoel P Paquot F Malaise O Cavalier E Delanaye P Sclerostin within the chronic kidney disease spectrum Clin Chim Acta 2020 502 84 90 10.1016/j.cca.2019.12.008 31866333
Bouquegneau A, Evenepoel P, Paquot F, Malaise O, Cavalier E, Delanaye P (2020) Sclerostin within the chronic kidney disease spectrum. Clin Chim Acta 502:84–90. 10.1016/j.cca.2019.12.00831866333 10.1016/j.cca.2019.12.008
33. Riddle RC Endocrine functions of sclerostin Curr Opin Endocr Metab Res 2023 10.1016/j.coemr.2022.100433 36713826
Riddle RC (2023) Endocrine functions of sclerostin. Curr Opin Endocr Metab Res. 10.1016/j.coemr.2022.10043336713826 10.1016/j.coemr.2022.100433
34. Kirkpantur A Balci M Turkvatan A Afsar B Serum sclerostin levels, arteriovenous fistula calcification and 2-years all-cause mortality in prevalent hemodialysis patients Nefrologia 2016 36 1 24 32 10.1016/j.nefro.2015.07.006 26546060
Kirkpantur A, Balci M, Turkvatan A, Afsar B (2016) Serum sclerostin levels, arteriovenous fistula calcification and 2-years all-cause mortality in prevalent hemodialysis patients. Nefrologia 36(1):24–32. 10.1016/j.nefro.2015.07.00626546060 10.1016/j.nefro.2015.07.006
35. Kirkpantur A Balci M Turkvatan A Afsar B Independent association between serum sclerostin levels and carotid artery atherosclerosis in prevalent haemodialysis patients Clin Kidney J 2015 8 6 737 743 10.1093/ckj/sfv077 26613034
Kirkpantur A, Balci M, Turkvatan A, Afsar B (2015) Independent association between serum sclerostin levels and carotid artery atherosclerosis in prevalent haemodialysis patients. Clin Kidney J 8(6):737–743. 10.1093/ckj/sfv07726613034 10.1093/ckj/sfv077
36. Makówka A Głyda M Majewska ER Nowicki M Varying patterns of biomarkers of mineral and bone metabolism after kidney transplantation Horm Metab Res 2017 49 8 618 624 10.1055/s-0043-112349 28679143
Makówka A, Głyda M, Majewska ER, Nowicki M (2017) Varying patterns of biomarkers of mineral and bone metabolism after kidney transplantation. Horm Metab Res 49(8):618–624. 10.1055/s-0043-11234928679143 10.1055/s-0043-112349
37. Hernandez MJ Dos Reis LM Marques ID Araujo MJ Truyts CAM Oliveira IB Barreto FC David-Neto E Custodio MR Moyses RM Bellorin-Font E Jorgetti V The effect of vitamin D and zoledronic acid in bone marrow adiposity in kidney transplant patients: a post hoc analysis PLoS ONE 2018 13 5 e0197994 10.1371/journal.pone.0197994 29799857
Hernandez MJ, Dos Reis LM, Marques ID, Araujo MJ, Truyts CAM, Oliveira IB, Barreto FC, David-Neto E, Custodio MR, Moyses RM, Bellorin-Font E, Jorgetti V (2018) The effect of vitamin D and zoledronic acid in bone marrow adiposity in kidney transplant patients: a post hoc analysis. PLoS ONE 13(5):e0197994. 10.1371/journal.pone.019799429799857 10.1371/journal.pone.0197994
38. Araújo M Bacelar Marques ID Graciolli FG Fukuhara L Machado Dos Reis L Custódio M Jorgetti V Elias RM David-Neto E Moysés RMA Comparison of serum levels with bone content and gene expression indicate a contradictory effect of kidney transplantation on sclerostin Kidney Int 2019 96 5 1100 1104 10.1016/j.kint.2019.06.007 31526513
Araújo M, Bacelar Marques ID, Graciolli FG, Fukuhara L, Machado Dos Reis L, Custódio M, Jorgetti V, Elias RM, David-Neto E, Moysés RMA (2019) Comparison of serum levels with bone content and gene expression indicate a contradictory effect of kidney transplantation on sclerostin. Kidney Int 96(5):1100–1104. 10.1016/j.kint.2019.06.00731526513 10.1016/j.kint.2019.06.007
39. Evenepoel P Claes K Meijers B Laurent MR Bammens B Naesens M Sprangers B Cavalier E Kuypers D Natural history of mineral metabolism, bone turnover and bone mineral density in de novo renal transplant recipients treated with a steroid minimization immunosuppressive protocol Nephrol Dial Transplant 2020 35 4 697 705 10.1093/ndt/gfy306 30339234
Evenepoel P, Claes K, Meijers B, Laurent MR, Bammens B, Naesens M, Sprangers B, Cavalier E, Kuypers D (2020) Natural history of mineral metabolism, bone turnover and bone mineral density in de novo renal transplant recipients treated with a steroid minimization immunosuppressive protocol. Nephrol Dial Transplant 35(4):697–705. 10.1093/ndt/gfy30630339234 10.1093/ndt/gfy306
40. Chang MK Kramer I Huber T Kinzel B Guth-Gundel S Leupin O Kneissel M Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels Proc Natl Acad Sci USA 2014 111 48 E5187 5195 10.1073/pnas.1413828111 25404300
Chang MK, Kramer I, Huber T, Kinzel B, Guth-Gundel S, Leupin O, Kneissel M (2014) Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels. Proc Natl Acad Sci USA 111(48):E5187-519525404300 10.1073/pnas.1413828111
41. Cejka D Marculescu R Kozakowski N Plischke M Reiter T Gessl A Haas M Renal elimination of sclerostin increases with declining kidney function J Clin Endocrinol Metab 2014 99 1 248 255 10.1210/jc.2013-2786 24187403
Cejka D, Marculescu R, Kozakowski N, Plischke M, Reiter T, Gessl A, Haas M (2014) Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab 99(1):248–255. 10.1210/jc.2013-278624187403 10.1210/jc.2013-2786
42. Pelletier S Dubourg L Carlier MC Hadj-Aissa A Fouque D The relation between renal function and serum sclerostin in adult patients with CKD Clin J Am Soc Nephrol 2013 8 5 819 823 10.2215/cjn.07670712 23430206
Pelletier S, Dubourg L, Carlier MC, Hadj-Aissa A, Fouque D (2013) The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol 8(5):819–823. 10.2215/cjn.0767071223430206 10.2215/cjn.07670712
43. Kakareko K Rydzewska-Rosolowska A Brzosko S Gozdzikiewicz-Lapinska J Koc-Zorawska E Samocik P Kozlowski R Mysliwiec M Naumnik B Hryszko T Renal handling of sclerostin in response to acute glomerular filtration decline Horm Metab Res 2016 48 7 457 461 10.1055/s-0042-107791 27214309
Kakareko K, Rydzewska-Rosolowska A, Brzosko S, Gozdzikiewicz-Lapinska J, Koc-Zorawska E, Samocik P, Kozlowski R, Mysliwiec M, Naumnik B, Hryszko T (2016) Renal handling of sclerostin in response to acute glomerular filtration decline. Horm Metab Res 48(7):457–461. 10.1055/s-0042-10779127214309 10.1055/s-0042-107791
44. Kulkarni NH Halladay DL Miles RR Gilbert LM Frolik CA Galvin RJ Martin TJ Gillespie MT Onyia JE Effects of parathyroid hormone on Wnt signaling pathway in bone J Cell Biochem 2005 95 6 1178 1190 10.1002/jcb.20506 15962290
Kulkarni NH, Halladay DL, Miles RR, Gilbert LM, Frolik CA, Galvin RJ, Martin TJ, Gillespie MT, Onyia JE (2005) Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem 95(6):1178–1190. 10.1002/jcb.2050615962290 10.1002/jcb.20506
45. Gifre L Ruiz-Gaspà S Monegal A Nomdedeu B Filella X Guañabens N Peris P Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover Bone 2013 57 1 272 276 10.1016/j.bone.2013.08.016 23981659
Gifre L, Ruiz-Gaspà S, Monegal A, Nomdedeu B, Filella X, Guañabens N, Peris P (2013) Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover. Bone 57(1):272–276. 10.1016/j.bone.2013.08.01623981659 10.1016/j.bone.2013.08.016
46. Beier EE Sheu TJ Resseguie EA Takahata M Awad HA Cory-Slechta DA Puzas JE Sclerostin activity plays a key role in the negative effect of glucocorticoid signaling on osteoblast function in mice Bone Res 2017 5 17013 10.1038/boneres.2017.13 28529816
Beier EE, Sheu TJ, Resseguie EA, Takahata M, Awad HA, Cory-Slechta DA, Puzas JE (2017) Sclerostin activity plays a key role in the negative effect of glucocorticoid signaling on osteoblast function in mice. Bone Res 5:17013. 10.1038/boneres.2017.1328529816 10.1038/boneres.2017.13
47. Brabnikova Maresova K Pavelka K Stepan JJ Acute effects of glucocorticoids on serum markers of osteoclasts, osteoblasts, and osteocytes Calcif Tissue Int 2013 92 4 354 361 10.1007/s00223-012-9684-4 23247536
Brabnikova Maresova K, Pavelka K, Stepan JJ (2013) Acute effects of glucocorticoids on serum markers of osteoclasts, osteoblasts, and osteocytes. Calcif Tissue Int 92(4):354–361. 10.1007/s00223-012-9684-423247536 10.1007/s00223-012-9684-4
48. Boltenstål H Qureshi AR Behets GJ Lindholm B Stenvinkel P D'Haese PC Haarhaus M Association of serum sclerostin with bone sclerostin in chronic kidney disease is lost in glucocorticoid treated patients Calcif Tissue Int 2019 104 2 214 223 10.1007/s00223-018-0491-4 30406279
Boltenstål H, Qureshi AR, Behets GJ, Lindholm B, Stenvinkel P, D’Haese PC, Haarhaus M (2019) Association of serum sclerostin with bone sclerostin in chronic kidney disease is lost in glucocorticoid treated patients. Calcif Tissue Int 104(2):214–223. 10.1007/s00223-018-0491-430406279 10.1007/s00223-018-0491-4
49. Sato AY Cregor M Delgado-Calle J Condon KW Allen MR Peacock M Plotkin LI Bellido T Protection from glucocorticoid-induced osteoporosis by anti-catabolic signaling in the absence of Sost/sclerostin J Bone Miner Res 2016 31 10 1791 1802 10.1002/jbmr.2869 27163932
Sato AY, Cregor M, Delgado-Calle J, Condon KW, Allen MR, Peacock M, Plotkin LI, Bellido T (2016) Protection from glucocorticoid-induced osteoporosis by anti-catabolic signaling in the absence of Sost/sclerostin. J Bone Miner Res 31(10):1791–1802. 10.1002/jbmr.286927163932 10.1002/jbmr.2869
50. Maré A Verhulst A Cavalier E Delanaye P Behets GJ Meijers B Kuypers D D'Haese PC Evenepoel P Clinical inference of serum and bone sclerostin levels in patients with end-stage kidney disease J Clin Med 2019 10.3390/jcm8122027 31756992
Maré A, Verhulst A, Cavalier E, Delanaye P, Behets GJ, Meijers B, Kuypers D, D’Haese PC, Evenepoel P (2019) Clinical inference of serum and bone sclerostin levels in patients with end-stage kidney disease. J Clin Med. 10.3390/jcm812202731756992 10.3390/jcm8122027
51. Jørgensen HS Claes K Smout D Naesens M Kuypers D D'Haese P Cavalier E Evenepoel P Associations of changes in bone turnover markers with change in bone mineral density in kidney transplant patients Clin J Am Soc Nephrol 2024 19 4 483 493 10.2215/cjn.0000000000000368 38030558
Jørgensen HS, Claes K, Smout D, Naesens M, Kuypers D, D’Haese P, Cavalier E, Evenepoel P (2024) Associations of changes in bone turnover markers with change in bone mineral density in kidney transplant patients. Clin J Am Soc Nephrol 19(4):483–493. 10.2215/cjn.000000000000036838030558 10.2215/cjn.0000000000000368
52. Mödder UI Hoey KA Amin S McCready LK Achenbach SJ Riggs BL Melton LJ III Khosla S Relation of age, gender, and bone mass to circulating sclerostin levels in women and men J Bone Miner Res 2011 26 2 373 379 10.1002/jbmr.217 20721932
Mödder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, Melton LJ III, Khosla S (2011) Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res 26(2):373–379. 10.1002/jbmr.21720721932 10.1002/jbmr.217
53. Ishimura E Okuno S Ichii M Norimine K Yamakawa T Shoji S Nishizawa Y Inaba M Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients J Clin Endocrinol Metab 2014 99 11 4315 4320 10.1210/jc.2014-2372 25093620
Ishimura E, Okuno S, Ichii M, Norimine K, Yamakawa T, Shoji S, Nishizawa Y, Inaba M (2014) Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients. J Clin Endocrinol Metab 99(11):4315–4320. 10.1210/jc.2014-237225093620 10.1210/jc.2014-2372
54. Carlini RG Rojas E Weisinger JR Lopez M Martinis R Arminio A Bellorin-Font E Bone disease in patients with long-term renal transplantation and normal renal function Am J Kidney Dis 2000 36 1 160 166 10.1053/ajkd.2000.8289 10873886
Carlini RG, Rojas E, Weisinger JR, Lopez M, Martinis R, Arminio A, Bellorin-Font E (2000) Bone disease in patients with long-term renal transplantation and normal renal function. Am J Kidney Dis 36(1):160–166. 10.1053/ajkd.2000.828910873886 10.1053/ajkd.2000.8289
55. Pietrzyk B Wyskida K Ficek J Kolonko A Ficek R Więcek A Olszanecka-Glinianowicz M Chudek J Relationship between plasma levels of sclerostin, calcium-phosphate disturbances, established markers of bone turnover, and inflammation in haemodialysis patients Int Urol Nephrol 2019 51 3 519 526 10.1007/s11255-018-2050-3 30584645
Pietrzyk B, Wyskida K, Ficek J, Kolonko A, Ficek R, Więcek A, Olszanecka-Glinianowicz M, Chudek J (2019) Relationship between plasma levels of sclerostin, calcium-phosphate disturbances, established markers of bone turnover, and inflammation in haemodialysis patients. Int Urol Nephrol 51(3):519–526. 10.1007/s11255-018-2050-330584645 10.1007/s11255-018-2050-3
56. Carpenter KA Ross RD Sclerostin antibody treatment increases bone mass and normalizes circulating phosphate levels in growing Hyp mice J Bone Miner Res 2020 35 3 596 607 10.1002/jbmr.3923 31743490
Carpenter KA, Ross RD (2020) Sclerostin antibody treatment increases bone mass and normalizes circulating phosphate levels in growing Hyp mice. J Bone Miner Res 35(3):596–607. 10.1002/jbmr.392331743490 10.1002/jbmr.3923
57. Michigami T Roles of osteocytes in phosphate metabolism Front Endocrinol (Lausanne) 2022 13 967774 10.3389/fendo.2022.967774 35909535
Michigami T (2022) Roles of osteocytes in phosphate metabolism. Front Endocrinol (Lausanne) 13:967774. 10.3389/fendo.2022.96777435909535 10.3389/fendo.2022.967774
58. Ito N Prideaux M Wijenayaka AR Yang D Ormsby RT Bonewald LF Atkins GJ Sclerostin directly stimulates osteocyte synthesis of fibroblast growth factor-23 Calcif Tissue Int 2021 109 1 66 76 10.1007/s00223-021-00823-6 33616712
Ito N, Prideaux M, Wijenayaka AR, Yang D, Ormsby RT, Bonewald LF, Atkins GJ (2021) Sclerostin directly stimulates osteocyte synthesis of fibroblast growth factor-23. Calcif Tissue Int 109(1):66–76. 10.1007/s00223-021-00823-633616712 10.1007/s00223-021-00823-6
59. Bellido T Ali AA Gubrij I Plotkin LI Fu Q O'Brien CA Manolagas SC Jilka RL Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis Endocrinology 2005 146 11 4577 4583 10.1210/en.2005-0239 16081646
Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O’Brien CA, Manolagas SC, Jilka RL (2005) Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146(11):4577–4583. 10.1210/en.2005-023916081646 10.1210/en.2005-0239
60. Zuo J Hasan AA Hocher CF Kalk P Kleuser B Krämer BK Hocher B Inverse correlation of intact PTH, oxidized PTH as well as non-oxidized PTH with 25-hydroxyvitamin D3 in kidney transplant recipients Front Endocrinol (Lausanne) 2023 14 1178166 10.3389/fendo.2023.1178166 37324252
Zuo J, Hasan AA, Hocher CF, Kalk P, Kleuser B, Krämer BK, Hocher B (2023) Inverse correlation of intact PTH, oxidized PTH as well as non-oxidized PTH with 25-hydroxyvitamin D3 in kidney transplant recipients. Front Endocrinol (Lausanne) 14:1178166. 10.3389/fendo.2023.117816637324252 10.3389/fendo.2023.1178166
61. Ryan ZC Ketha H McNulty MS McGee-Lawrence M Craig TA Grande JP Westendorf JJ Singh RJ Kumar R Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium Proc Natl Acad Sci USA 2013 110 15 6199 6204 10.1073/pnas.1221255110 23530237
Ryan ZC, Ketha H, McNulty MS, McGee-Lawrence M, Craig TA, Grande JP, Westendorf JJ, Singh RJ, Kumar R (2013) Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium. Proc Natl Acad Sci USA 110(15):6199–6204. 10.1073/pnas.122125511023530237 10.1073/pnas.1221255110
62. Bowe AE Finnegan R Jan de Beur SM Cho J Levine MA Kumar R Schiavi SC FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate Biochem Biophys Res Commun 2001 284 4 977 981 10.1006/bbrc.2001.5084 11409890
Bowe AE, Finnegan R, Jan de Beur SM, Cho J, Levine MA, Kumar R, Schiavi SC (2001) FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 284(4):977–981. 10.1006/bbrc.2001.508411409890 10.1006/bbrc.2001.5084
63. Kim J Han W Park T Kim EJ Bang I Lee HS Jeong Y Roh K Kim J Kim JS Kang C Seok C Han JK Choi HJ Sclerostin inhibits Wnt signaling through tandem interaction with two LRP6 ectodomains Nat Commun 2020 11 1 5357 10.1038/s41467-020-19155-4 33097721
Kim J, Han W, Park T, Kim EJ, Bang I, Lee HS, Jeong Y, Roh K, Kim J, Kim JS, Kang C, Seok C, Han JK, Choi HJ (2020) Sclerostin inhibits Wnt signaling through tandem interaction with two LRP6 ectodomains. Nat Commun 11(1):5357. 10.1038/s41467-020-19155-433097721 10.1038/s41467-020-19155-4
64. Padhi D Allison M Kivitz AJ Gutierrez MJ Stouch B Wang C Jang G Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study J Clin Pharmacol 2014 54 2 168 178 10.1002/jcph.239 24272917
Padhi D, Allison M, Kivitz AJ, Gutierrez MJ, Stouch B, Wang C, Jang G (2014) Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study. J Clin Pharmacol 54(2):168–178. 10.1002/jcph.23924272917 10.1002/jcph.239
65. Arasu A Cawthon PM Lui LY Do TP Arora PS Cauley JA Ensrud KE Cummings SR Serum sclerostin and risk of hip fracture in older Caucasian women J Clin Endocrinol Metab 2012 97 6 2027 2032 10.1210/jc.2011-3419 22466341
Arasu A, Cawthon PM, Lui LY, Do TP, Arora PS, Cauley JA, Ensrud KE, Cummings SR (2012) Serum sclerostin and risk of hip fracture in older Caucasian women. J Clin Endocrinol Metab 97(6):2027–2032. 10.1210/jc.2011-341922466341 10.1210/jc.2011-3419
66. Ardawi MS Rouzi AA Al-Sibiani SA Al-Senani NS Qari MH Mousa SA High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for Osteoporosis Research Study J Bone Miner Res 2012 27 12 2592 2602 10.1002/jbmr.1718 22836717
Ardawi MS, Rouzi AA, Al-Sibiani SA, Al-Senani NS, Qari MH, Mousa SA (2012) High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for Osteoporosis Research Study. J Bone Miner Res 27(12):2592–2602. 10.1002/jbmr.171822836717 10.1002/jbmr.1718
67. Cosman F Crittenden DB Adachi JD Binkley N Czerwinski E Ferrari S Hofbauer LC Lau E Lewiecki EM Miyauchi A Zerbini CA Milmont CE Chen L Maddox J Meisner PD Libanati C Grauer A Romosozumab treatment in postmenopausal women with osteoporosis N Engl J Med 2016 375 16 1532 1543 10.1056/NEJMoa1607948 27641143
Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375(16):1532–1543. 10.1056/NEJMoa160794827641143 10.1056/NEJMoa1607948
68. Sato M Inaba M Yamada S Emoto M Ohno Y Tsujimoto Y Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study J Bone Miner Metab 2021 39 6 1082 1090 10.1007/s00774-021-01253-y 34324082
Sato M, Inaba M, Yamada S, Emoto M, Ohno Y, Tsujimoto Y (2021) Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study. J Bone Miner Metab 39(6):1082–1090. 10.1007/s00774-021-01253-y34324082 10.1007/s00774-021-01253-y
69. Fixen C Tunoa J Romosozumab: a review of efficacy, safety, and cardiovascular risk Curr Osteoporos Rep 2021 19 1 15 22 10.1007/s11914-020-00652-w 33409990
Fixen C, Tunoa J (2021) Romosozumab: a review of efficacy, safety, and cardiovascular risk. Curr Osteoporos Rep 19(1):15–22. 10.1007/s11914-020-00652-w33409990 10.1007/s11914-020-00652-w
70. Podestà MA Cucchiari D Ciceri P Messa P Torregrosa JV Cozzolino M Cardiovascular calcifications in kidney transplant recipients Nephrol Dial Transplant 2022 37 11 2063 2071 10.1093/ndt/gfab053 33620476
Podestà MA, Cucchiari D, Ciceri P, Messa P, Torregrosa JV, Cozzolino M (2022) Cardiovascular calcifications in kidney transplant recipients. Nephrol Dial Transplant 37(11):2063–2071. 10.1093/ndt/gfab05333620476 10.1093/ndt/gfab053
71. Wu M Rementer C Giachelli CM Vascular calcification: an update on mechanisms and challenges in treatment Calcif Tissue Int 2013 93 4 365 373 10.1007/s00223-013-9712-z 23456027
Wu M, Rementer C, Giachelli CM (2013) Vascular calcification: an update on mechanisms and challenges in treatment. Calcif Tissue Int 93(4):365–373. 10.1007/s00223-013-9712-z23456027 10.1007/s00223-013-9712-z
72. Staines KA MacRae VE Farquharson C The importance of the SIBLING family of proteins on skeletal mineralisation and bone remodelling J Endocrinol 2012 214 3 241 255 10.1530/joe-12-0143 22700194
Staines KA, MacRae VE, Farquharson C (2012) The importance of the SIBLING family of proteins on skeletal mineralisation and bone remodelling. J Endocrinol 214(3):241–255. 10.1530/joe-12-014322700194 10.1530/joe-12-0143
73. da Silva RA da Feltran SG Do Fernandes CCJ Zambuzzi WF Osteogenic gene markers are epigenetically reprogrammed during contractile-to-calcifying vascular smooth muscle cell phenotype transition Cell Signal 2020 66 109458 10.1016/j.cellsig.2019.109458 31678252
da Silva RA, da Feltran SG, Do Fernandes CCJ, Zambuzzi WF (2020) Osteogenic gene markers are epigenetically reprogrammed during contractile-to-calcifying vascular smooth muscle cell phenotype transition. Cell Signal 66:109458. 10.1016/j.cellsig.2019.10945831678252 10.1016/j.cellsig.2019.109458
74. Schinzari F Tesauro M Bertoli A Valentini A Veneziani A Campia U Cardillo C Calcification biomarkers and vascular dysfunction in obesity and type 2 diabetes: influence of oral hypoglycemic agents Am J Physiol Endocrinol Metab 2019 317 4 E658 E666 10.1152/ajpendo.00204.2019 31408377
Schinzari F, Tesauro M, Bertoli A, Valentini A, Veneziani A, Campia U, Cardillo C (2019) Calcification biomarkers and vascular dysfunction in obesity and type 2 diabetes: influence of oral hypoglycemic agents. Am J Physiol Endocrinol Metab 317(4):E658–E666. 10.1152/ajpendo.00204.201931408377 10.1152/ajpendo.00204.2019
75. Villa-Bellosta R Vascular calcification: key roles of phosphate and pyrophosphate Int J Mol Sci 2021 10.3390/ijms222413536 34948333
Villa-Bellosta R (2021) Vascular calcification: key roles of phosphate and pyrophosphate. Int J Mol Sci. 10.3390/ijms22241353634948333 10.3390/ijms222413536
76. Pan W Jie W Huang H (2023) Vascular calcification: molecular mechanisms and therapeutic interventions MedComm 2020 4 1 e200 10.1002/mco2.200
Pan W, Jie W (2020) Huang H (2023) Vascular calcification: molecular mechanisms and therapeutic interventions. MedComm 4(1):e200. 10.1002/mco2.20010.1002/mco2.200
77. Tyson KL Reynolds JL McNair R Zhang Q Weissberg PL Shanahan CM Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification Arterioscler Thromb Vasc Biol 2003 23 3 489 494 10.1161/01.Atv.0000059406.92165.31 12615658
Tyson KL, Reynolds JL, McNair R, Zhang Q, Weissberg PL, Shanahan CM (2003) Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol 23(3):489–494. 10.1161/01.Atv.0000059406.92165.3112615658 10.1161/01.Atv.0000059406.92165.31
78. Zhu D Mackenzie NC Millán JL Farquharson C MacRae VE The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells PLoS ONE 2011 6 5 e19595 10.1371/journal.pone.0019595 21611184
Zhu D, Mackenzie NC, Millán JL, Farquharson C, MacRae VE (2011) The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS ONE 6(5):e19595. 10.1371/journal.pone.001959521611184 10.1371/journal.pone.0019595
79. Evenepoel P D'Haese P Brandenburg V Sclerostin and DKK1: new players in renal bone and vascular disease Kidney Int 2015 88 2 235 240 10.1038/ki.2015.156 26083653
Evenepoel P, D’Haese P, Brandenburg V (2015) Sclerostin and DKK1: new players in renal bone and vascular disease. Kidney Int 88(2):235–240. 10.1038/ki.2015.15626083653 10.1038/ki.2015.156
80. Bisson SK Ung RV Picard S Valade D Agharazii M Larivière R Mac-Way F High calcium, phosphate and calcitriol supplementation leads to an osteocyte-like phenotype in calcified vessels and bone mineralisation defect in uremic rats J Bone Miner Metab 2019 37 2 212 223 10.1007/s00774-018-0919-y 29603070
Bisson SK, Ung RV, Picard S, Valade D, Agharazii M, Larivière R, Mac-Way F (2019) High calcium, phosphate and calcitriol supplementation leads to an osteocyte-like phenotype in calcified vessels and bone mineralisation defect in uremic rats. J Bone Miner Metab 37(2):212–223. 10.1007/s00774-018-0919-y29603070 10.1007/s00774-018-0919-y
81. Nordholm A Mace ML Gravesen E Hofman-Bang J Morevati M Olgaard K Lewin E Klotho and activin A in kidney injury: plasma Klotho is maintained in unilateral obstruction despite no upregulation of Klotho biosynthesis in the contralateral kidney Am J Physiol Ren Physiol 2018 314 5 F753 F762 10.1152/ajprenal.00528.2017
Nordholm A, Mace ML, Gravesen E, Hofman-Bang J, Morevati M, Olgaard K, Lewin E (2018) Klotho and activin A in kidney injury: plasma Klotho is maintained in unilateral obstruction despite no upregulation of Klotho biosynthesis in the contralateral kidney. Am J Physiol Ren Physiol 314(5):F753–F762. 10.1152/ajprenal.00528.201710.1152/ajprenal.00528.2017
82. Rukov JL Gravesen E Mace ML Hofman-Bang J Vinther J Andersen CB Lewin E Olgaard K Effect of chronic uremia on the transcriptional profile of the calcified aorta analyzed by RNA sequencing Am J Physiol Ren Physiol 2016 310 6 F477 491 10.1152/ajprenal.00472.2015
Rukov JL, Gravesen E, Mace ML, Hofman-Bang J, Vinther J, Andersen CB, Lewin E, Olgaard K (2016) Effect of chronic uremia on the transcriptional profile of the calcified aorta analyzed by RNA sequencing. Am J Physiol Ren Physiol 310(6):F477-491. 10.1152/ajprenal.00472.201510.1152/ajprenal.00472.2015
83. Nguyen-Yamamoto L Tanaka KI St-Arnaud R Goltzman D Vitamin D-regulated osteocytic sclerostin and BMP2 modulate uremic extraskeletal calcification JCI Insight 2019 10.1172/jci.insight.126467 31292298
Nguyen-Yamamoto L, Tanaka KI, St-Arnaud R, Goltzman D (2019) Vitamin D-regulated osteocytic sclerostin and BMP2 modulate uremic extraskeletal calcification. JCI Insight. 10.1172/jci.insight.12646731292298 10.1172/jci.insight.126467
84. Krishna SM Seto SW Jose RJ Li J Morton SK Biros E Wang Y Nsengiyumva V Lindeman JH Loots GG Rush CM Craig JM Golledge J Wnt signaling pathway inhibitor sclerostin inhibits angiotensin II-induced aortic aneurysm and atherosclerosis Arterioscler Thromb Vasc Biol 2017 37 3 553 566 10.1161/atvbaha.116.308723 28062506
Krishna SM, Seto SW, Jose RJ, Li J, Morton SK, Biros E, Wang Y, Nsengiyumva V, Lindeman JH, Loots GG, Rush CM, Craig JM, Golledge J (2017) Wnt signaling pathway inhibitor sclerostin inhibits angiotensin II-induced aortic aneurysm and atherosclerosis. Arterioscler Thromb Vasc Biol 37(3):553–566. 10.1161/atvbaha.116.30872328062506 10.1161/atvbaha.116.308723
85. Viaene L Behets GJ Claes K Meijers B Blocki F Brandenburg V Evenepoel P D'Haese PC Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis? Nephrol Dial Transplant 2013 28 12 3024 3030 10.1093/ndt/gft039 23605174
Viaene L, Behets GJ, Claes K, Meijers B, Blocki F, Brandenburg V, Evenepoel P, D’Haese PC (2013) Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis? Nephrol Dial Transplant 28(12):3024–3030. 10.1093/ndt/gft03923605174 10.1093/ndt/gft039
86. De Maré A Maudsley S Azmi A Hendrickx JO Opdebeeck B Neven E D'Haese PC Verhulst A Sclerostin as regulatory molecule in vascular media calcification and the bone–vascular axis Toxins (Basel) 2019 10.3390/toxins11070428 31330917
De Maré A, Maudsley S, Azmi A, Hendrickx JO, Opdebeeck B, Neven E, D’Haese PC, Verhulst A (2019) Sclerostin as regulatory molecule in vascular media calcification and the bone–vascular axis. Toxins (Basel). 10.3390/toxins1107042831330917 10.3390/toxins11070428
87. Claes KJ Viaene L Heye S Meijers B d'Haese P Evenepoel P Sclerostin: another vascular calcification inhibitor? J Clin Endocrinol Metab 2013 98 8 3221 3228 10.1210/jc.2013-1521 23788689
Claes KJ, Viaene L, Heye S, Meijers B, d’Haese P, Evenepoel P (2013) Sclerostin: another vascular calcification inhibitor? J Clin Endocrinol Metab 98(8):3221–3228. 10.1210/jc.2013-152123788689 10.1210/jc.2013-1521
88. De Maré A Opdebeeck B Neven E D'Haese PC Verhulst A Sclerostin protects against vascular calcification development in mice J Bone Miner Res 2022 37 4 687 699 10.1002/jbmr.4503 35038187
De Maré A, Opdebeeck B, Neven E, D’Haese PC, Verhulst A (2022) Sclerostin protects against vascular calcification development in mice. J Bone Miner Res 37(4):687–69935038187 10.1002/jbmr.4503
89. Roforth MM Fujita K McGregor UI Kirmani S McCready LK Peterson JM Drake MT Monroe DG Khosla S Effects of age on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in humans Bone 2014 59 1 6 10.1016/j.bone.2013.10.019 24184314
Roforth MM, Fujita K, McGregor UI, Kirmani S, McCready LK, Peterson JM, Drake MT, Monroe DG, Khosla S (2014) Effects of age on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in humans. Bone 59:1–6. 10.1016/j.bone.2013.10.01924184314 10.1016/j.bone.2013.10.019
90. Mace ML Gravesen E Nordholm A Egstrand S Morevati M Nielsen C Kjaer A Behets G D'Haese P Olgaard K Lewin E Chronic kidney disease-induced vascular calcification impairs bone metabolism J Bone Miner Res 2021 36 3 510 522 10.1002/jbmr.4203 33301619
Mace ML, Gravesen E, Nordholm A, Egstrand S, Morevati M, Nielsen C, Kjaer A, Behets G, D’Haese P, Olgaard K, Lewin E (2021) Chronic kidney disease-induced vascular calcification impairs bone metabolism. J Bone Miner Res 36(3):510–522. 10.1002/jbmr.420333301619 10.1002/jbmr.4203
91. Cheddani L Radulescu C Chaignon M Karras A Neuzillet Y Duong JP Tabibzadeh N Letavernier E Delahousse M Haymann JP From arterial stiffness to kidney graft microvasculature: mortality and graft survival within a cohort of 220 kidney transplant recipients PLoS ONE 2018 13 5 e0195928 10.1371/journal.pone.0195928 29723212
Cheddani L, Radulescu C, Chaignon M, Karras A, Neuzillet Y, Duong JP, Tabibzadeh N, Letavernier E, Delahousse M, Haymann JP (2018) From arterial stiffness to kidney graft microvasculature: mortality and graft survival within a cohort of 220 kidney transplant recipients. PLoS ONE 13(5):e0195928. 10.1371/journal.pone.019592829723212 10.1371/journal.pone.0195928
92. Dahle DO Eide IA Åsberg A Leivestad T Holdaas H Jenssen TG Fagerland MW Pihlstrøm H Mjøen G Hartmann A Aortic stiffness in a mortality risk calculator for kidney transplant recipients Transplantation 2015 99 8 1730 1737 10.1097/tp.0000000000000660 25757216
Dahle DO, Eide IA, Åsberg A, Leivestad T, Holdaas H, Jenssen TG, Fagerland MW, Pihlstrøm H, Mjøen G, Hartmann A (2015) Aortic stiffness in a mortality risk calculator for kidney transplant recipients. Transplantation 99(8):1730–1737. 10.1097/tp.000000000000066025757216 10.1097/tp.0000000000000660
93. Mitchell A Opazo Saez A Kos M Witzke O Kribben A Nürnberger J Pulse wave velocity predicts mortality in renal transplant patients Eur J Med Res 2010 15 10 452 455 10.1186/2047-783x-15-10-452 21156404
Mitchell A, Opazo Saez A, Kos M, Witzke O, Kribben A, Nürnberger J (2010) Pulse wave velocity predicts mortality in renal transplant patients. Eur J Med Res 15(10):452–455. 10.1186/2047-783x-15-10-45221156404 10.1186/2047-783x-15-10-452
94. Kim HS Seung J Lee JH Chung BH Yang CW Clinical significance of pre-transplant arterial stiffness and the impact of kidney transplantation on arterial stiffness PLoS ONE 2015 10 9 e0139138 10.1371/journal.pone.0139138 26406607
Kim HS, Seung J, Lee JH, Chung BH, Yang CW (2015) Clinical significance of pre-transplant arterial stiffness and the impact of kidney transplantation on arterial stiffness. PLoS ONE 10(9):e0139138. 10.1371/journal.pone.013913826406607 10.1371/journal.pone.0139138
95. Mause SF Deck A Hennies M Kaesler N Evenepoel P Boisvert WA Janssen U Brandenburg VM Validation of commercially available ELISAs for the detection of circulating sclerostin in hemodialysis patients Discoveries (Craiova) 2016 4 1 e55 10.15190/d.2016.2 27088126
Mause SF, Deck A, Hennies M, Kaesler N, Evenepoel P, Boisvert WA, Janssen U, Brandenburg VM (2016) Validation of commercially available ELISAs for the detection of circulating sclerostin in hemodialysis patients. Discoveries (Craiova) 4(1):e55. 10.15190/d.2016.227088126 10.15190/d.2016.2
96. Moysés RM Jamal SA Graciolli FG dos Reis LM Elias RM Can we compare serum sclerostin results obtained with different assays in hemodialysis patients? Int Urol Nephrol 2015 47 5 847 850 10.1007/s11255-015-0971-7 25862239
Moysés RM, Jamal SA, Graciolli FG, dos Reis LM, Elias RM (2015) Can we compare serum sclerostin results obtained with different assays in hemodialysis patients? Int Urol Nephrol 47(5):847–850. 10.1007/s11255-015-0971-725862239 10.1007/s11255-015-0971-7
97. Delanaye P Paquot F Bouquegneau A Blocki F Krzesinski JM Evenepoel P Pottel H Cavalier E Sclerostin and chronic kidney disease: the assay impacts what we (thought to) know Nephrol Dial Transplant 2018 33 8 1404 1410 10.1093/ndt/gfx282 29048521
Delanaye P, Paquot F, Bouquegneau A, Blocki F, Krzesinski JM, Evenepoel P, Pottel H, Cavalier E (2018) Sclerostin and chronic kidney disease: the assay impacts what we (thought to) know. Nephrol Dial Transplant 33(8):1404–1410. 10.1093/ndt/gfx28229048521 10.1093/ndt/gfx282
98. Drechsler C Evenepoel P Vervloet MG Wanner C Ketteler M Marx N Floege J Dekker FW Brandenburg VM High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study Nephrol Dial Transplant 2015 30 2 288 293 10.1093/ndt/gfu301 25248363
Drechsler C, Evenepoel P, Vervloet MG, Wanner C, Ketteler M, Marx N, Floege J, Dekker FW, Brandenburg VM (2015) High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 30(2):288–293. 10.1093/ndt/gfu30125248363 10.1093/ndt/gfu301
99. Gonçalves FL Elias RM dos Reis LM Graciolli FG Zampieri FG Oliveira RB Jorgetti V Moysés RM Serum sclerostin is an independent predictor of mortality in hemodialysis patients BMC Nephrol 2014 15 190 10.1186/1471-2369-15-190 25465028
Gonçalves FL, Elias RM, dos Reis LM, Graciolli FG, Zampieri FG, Oliveira RB, Jorgetti V, Moysés RM (2014) Serum sclerostin is an independent predictor of mortality in hemodialysis patients. BMC Nephrol 15:190. 10.1186/1471-2369-15-19025465028 10.1186/1471-2369-15-190
100. Delanaye P Krzesinski JM Warling X Moonen M Smelten N Médart L Bruyère O Reginster JY Pottel H Cavalier E Clinical and biological determinants of sclerostin plasma concentration in hemodialysis patients Nephron Clin Pract 2014 128 1–2 127 134 10.1159/000366449 25377055
Delanaye P, Krzesinski JM, Warling X, Moonen M, Smelten N, Médart L, Bruyère O, Reginster JY, Pottel H, Cavalier E (2014) Clinical and biological determinants of sclerostin plasma concentration in hemodialysis patients. Nephron Clin Pract 128(1–2):127–134. 10.1159/00036644925377055 10.1159/000366449
101. Kanbay M Solak Y Siriopol D Aslan G Afsar B Yazici D Covic A Sclerostin, cardiovascular disease and mortality: a systematic review and meta-analysis Int Urol Nephrol 2016 48 12 2029 2042 10.1007/s11255-016-1387-8 27497736
Kanbay M, Solak Y, Siriopol D, Aslan G, Afsar B, Yazici D, Covic A (2016) Sclerostin, cardiovascular disease and mortality: a systematic review and meta-analysis. Int Urol Nephrol 48(12):2029–2042. 10.1007/s11255-016-1387-827497736 10.1007/s11255-016-1387-8
102. Robling AG Niziolek PJ Baldridge LA Condon KW Allen MR Alam I Mantila SM Gluhak-Heinrich J Bellido TM Harris SE Turner CH Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin J Biol Chem 2008 283 9 5866 5875 10.1074/jbc.M705092200 18089564
Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido TM, Harris SE, Turner CH (2008) Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 283(9):5866–5875. 10.1074/jbc.M70509220018089564 10.1074/jbc.M705092200
103. Brandenburg VM Kramann R Koos R Krüger T Schurgers L Mühlenbruch G Hübner S Gladziwa U Drechsler C Ketteler M Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study BMC Nephrol 2013 14 219 10.1186/1471-2369-14-219 24112318
Brandenburg VM, Kramann R, Koos R, Krüger T, Schurgers L, Mühlenbruch G, Hübner S, Gladziwa U, Drechsler C, Ketteler M (2013) Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study. BMC Nephrol 14:219. 10.1186/1471-2369-14-21924112318 10.1186/1471-2369-14-219
104. Qureshi AR Olauson H Witasp A Haarhaus M Brandenburg V Wernerson A Lindholm B Söderberg M Wennberg L Nordfors L Ripsweden J Barany P Stenvinkel P Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification Kidney Int 2015 88 6 1356 1364 10.1038/ki.2015.194 26331407
Qureshi AR, Olauson H, Witasp A, Haarhaus M, Brandenburg V, Wernerson A, Lindholm B, Söderberg M, Wennberg L, Nordfors L, Ripsweden J, Barany P, Stenvinkel P (2015) Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification. Kidney Int 88(6):1356–1364. 10.1038/ki.2015.19426331407 10.1038/ki.2015.194
105. Vestergaard Kvist A Faruque J Vallejo-Yagüe E Weiler S Winter EM Burden AM Cardiovascular safety profile of romosozumab: a pharmacovigilance analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) J Clin Med 2021 10.3390/jcm10081660 33924496
Vestergaard Kvist A, Faruque J, Vallejo-Yagüe E, Weiler S, Winter EM, Burden AM (2021) Cardiovascular safety profile of romosozumab: a pharmacovigilance analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS). J Clin Med. 10.3390/jcm1008166033924496 10.3390/jcm10081660
106. Mayer O Bruthans J Seidlerová J Gelžinský J Kučera R Karnosová P Mateřánková M Rychecká M Wohlfahrt P Cífková R Filipovský J Vermeer C Low vitamin K status, high sclerostin and mortality risk of stable coronary heart disease patients Biomark Med 2021 15 16 1465 1477 10.2217/bmm-2021-0168 34668399
Mayer O, Bruthans J, Seidlerová J, Gelžinský J, Kučera R, Karnosová P, Mateřánková M, Rychecká M, Wohlfahrt P, Cífková R, Filipovský J, Vermeer C (2021) Low vitamin K status, high sclerostin and mortality risk of stable coronary heart disease patients. Biomark Med 15(16):1465–1477. 10.2217/bmm-2021-016834668399 10.2217/bmm-2021-0168
107. Stavrinou E Sarafidis PA Loutradis C Memmos E Faitatzidou D Giamalis P Koumaras C Karagiannis A Papagianni A Associations of serum sclerostin and Dickkopf-related protein-1 proteins with future cardiovascular events and mortality in haemodialysis patients: a prospective cohort study Clin Kidney J 2021 14 4 1165 1172 10.1093/ckj/sfaa069 33841862
Stavrinou E, Sarafidis PA, Loutradis C, Memmos E, Faitatzidou D, Giamalis P, Koumaras C, Karagiannis A, Papagianni A (2021) Associations of serum sclerostin and Dickkopf-related protein-1 proteins with future cardiovascular events and mortality in haemodialysis patients: a prospective cohort study. Clin Kidney J 14(4):1165–117233841862 10.1093/ckj/sfaa069
108. Milovanova LY Dobrosmyslov IA Milovanov YS Taranova MV Kozlov VV Milovanova SY Kozevnikova EI Fibroblast growth factor-23 (FGF-23)/soluble Klotho protein (sKlotho)/sclerostin glycoprotein ratio disturbance is a novel risk factor for cardiovascular complications in ESRD patients receiving treatment with regular hemodialysis or hemodiafiltration Ter Arkh 2018 90 6 48 54 10.26442/terarkh201890648-54 30701904
Milovanova LY, Dobrosmyslov IA, Milovanov YS, Taranova MV, Kozlov VV, Milovanova SY, Kozevnikova EI (2018) Fibroblast growth factor-23 (FGF-23)/soluble Klotho protein (sKlotho)/sclerostin glycoprotein ratio disturbance is a novel risk factor for cardiovascular complications in ESRD patients receiving treatment with regular hemodialysis or hemodiafiltration. Ter Arkh 90(6):48–54. 10.26442/terarkh201890648-5430701904 10.26442/terarkh201890648-54
109. Mathold K Wanby P Brudin L Von SP Carlsson M Alterations in bone turnover markers in patients with noncardio-embolic ischemic stroke PLoS ONE 2018 13 11 e0207348 10.1371/journal.pone.0207348 30496210
Mathold K, Wanby P, Brudin L, Von SP, Carlsson M (2018) Alterations in bone turnover markers in patients with noncardio-embolic ischemic stroke. PLoS ONE 13(11):e0207348. 10.1371/journal.pone.020734830496210 10.1371/journal.pone.0207348
110. He XW Wang E Bao YY Wang F Zhu M Hu XF Jin XP High serum levels of sclerostin and Dickkopf-1 are associated with acute ischaemic stroke Atherosclerosis 2016 253 22 28 10.1016/j.atherosclerosis.2016.08.003 27573735
He XW, Wang E, Bao YY, Wang F, Zhu M, Hu XF, Jin XP (2016) High serum levels of sclerostin and Dickkopf-1 are associated with acute ischaemic stroke. Atherosclerosis 253:22–28. 10.1016/j.atherosclerosis.2016.08.00327573735 10.1016/j.atherosclerosis.2016.08.003
111. Brandenburg VM D'Haese P Deck A Mekahli D Meijers B Neven E Evenepoel P From skeletal to cardiovascular disease in 12 steps—the evolution of sclerostin as a major player in CKD–MBD Pediatr Nephrol 2016 31 2 195 206 10.1007/s00467-015-3069-7 25735207
Brandenburg VM, D’Haese P, Deck A, Mekahli D, Meijers B, Neven E, Evenepoel P (2016) From skeletal to cardiovascular disease in 12 steps—the evolution of sclerostin as a major player in CKD–MBD. Pediatr Nephrol 31(2):195–206. 10.1007/s00467-015-3069-725735207 10.1007/s00467-015-3069-7
112. Tomei P Zaza G Granata S Gatti D Fraccarollo C Gesualdo L Boschiero L Lupo A Sclerostin and Dickkopf-1 in post-menopausal renal allograft recipients Transplant Proc 2014 46 7 2241 2246 10.1016/j.transproceed.2014.07.024 25242761
Tomei P, Zaza G, Granata S, Gatti D, Fraccarollo C, Gesualdo L, Boschiero L, Lupo A (2014) Sclerostin and Dickkopf-1 in post-menopausal renal allograft recipients. Transplant Proc 46(7):2241–2246. 10.1016/j.transproceed.2014.07.02425242761 10.1016/j.transproceed.2014.07.024
113. Vigil FMB Vaz de Castro PAS Hasparyk UG Bartolomei VS Silva A Potential role of bone metabolism markers in kidney transplant recipients Curr Med Chem 2024 10.2174/0109298673250291231121052433 38332694
Vigil FMB, Vaz de Castro PAS, Hasparyk UG, Bartolomei VS, Silva A (2024) Potential role of bone metabolism markers in kidney transplant recipients. Curr Med Chem. 10.2174/010929867325029123112105243338332694 10.2174/0109298673250291231121052433
